More information:



[www.mitoeagle.org](http://www.mitoeagle.org/)

Funded by the Horizon 2020 Framework Programme of the European Union



1

2

3 **Mitochondrial respiratory states and rates:**

4 **Building blocks of mitochondrial physiology Part 1**

5

6 **COST Action CA15203 MitoEAGLE preprint** Version: 2018-10-17(44)

7

8 Corresponding author: Gnaiger E

9 Co-authors:

10 Aasander Frostner E, Abumrad NA, Acuna-Castroviejo D, Adams SH, Ahn B, Ali SS, Alves MG,

11 Amati F, Amoedo ND, Andreadou I, Aral C, Arandarčikaitė O, Arnould T, Avram VF, Bailey DM,

12 Bajpeyi S, Bakker BM, Bastos Sant'Anna Silva AC, Battino M, Bazil J, Beard DA, Bednarczyk P,

13 Bello F, Ben-Shachar D, Bergdahl A, Berge RK, Bernardi P, Bishop D, Blier PU, Blindheim DF,

14 Boetker HE, Boros M, Borsheim E, Borutaitė V, Bouillaud F, Bouitbir J, Boushel RC, Bovard J,

15 Breton S, Brown DA, Brown GC, Brown RA, Brozinick JT, Buettner GR, Burtscher J, Calabria E,

16 Calbet JA, Calzia E, Cannon DT, Cano Sanchez M, Canto AC, Cardoso LHD, Carvalho E, Casado

17 Pinna M, Cassina AM, Castro L, Cavalcanti-de-Albuquerque JP, Cervinkova Z, Chabi B, Chakrabarti

18 L, Chaurasia B, Chen Q, Chicco AJ, Chinopoulos C, Chowdhury SK, Cizmarova B, Clementi E, Coen

19 PM, Coker RH, Collin A, Crisóstomo L, Dambrova M, Danhelovska T, Darveau CA, Das AM, Dash

20 RK, Davidova E, Davis MS, De Goede P, De Palma C, Dembinska-Kiec A, Devaux Y, Di Marcello

21 M, Dias TR, Distefano G, Doermann N, Doerrier C, Donnelly C, Drahota Z, Dubouchaud H, Duchen

22 MR, Dumas JF, Durham WJ, Dymkowska D, Dyrstad SE, Dyson A, Dzialowski EM, Ehinger J, Elmer

23 E, Endlicher R, Engin AB, Escames G, Ezrova Z, Falk MJ, Fell DA, Ferdinandy P, Ferko M, Ferreira

24 JCB, Ferreira R, Fessel JP, Filipovska A, Fisar Z, Fischer M, Fisher G, Fisher JJ, Ford E, Fornaro M,

25 Galina A, Galkin A, Galli GL, Gan Z, Ganetzky R, Garcia-Roves PM, Garcia-Souza LF, Garipi E,

26 Garlid KD, Garrabou G, Garten A, Gastaldelli A, Genova ML, Giovarelli M, Gonzalez-Armenta JL,

27 Gonzalo H, Goodpaster BH, Gorr TA, Gourlay CW, Granata C, Grefte S, Guarch ME, Gueguen N,

28 Gumeni S, Haas CB, Haavik J, Haendeler J, Hamann A, Han J, Han WH, Hancock CR, Hand SC,

29 Hargreaves IP, Harrison DK, Hausenloy DJ, Heales SJR, Hellgren KT, Hepple RT, Hernansanz-

30 Agustin P, Hickey AJ, Hoel F, Holland OJ, Holloway GP, Hoppel CL, Hoppel F, Houstek J, Huete-

31 Ortega M, Iglesias-Gonzalez J, Irving BA, Iyer S, Jackson CB, Jadiya P, Jang DH, Jang YC, Janowska

32 J, Jansen-Dürr P, Jansone B, Jarmuszkiewicz W, Jespersen NR, Jha RK, Jurczak MJ, Jurk D, Kaambre

33 T, Kaczor JJ, Kainulainen H, Kandel SM, Kane DA, Kappler L, Karabatsiakis A, Karkucinska-

34 Wieckowska A, Keijer J, Keller MA, Keppner G, Khamoui AV, Kilbaugh T, Klepinin A, Klingenspor

35 M, Komlodi T, Koopman WJH, Kopitar-Jerala N, Kowaltowski AJ, Kozlov AV, Krajcova A, Krako

36 Jakovljevic N, Kristal BS, Kuang J, Kucera O, Kuka J, Kwak HB, Kwast K, Laasmaa M, Labieniec-

37 Watala M, Lai N, Land JM, Lane N, Laner V, Lanza IR, Larsen TS, Lavery GG, Lazou A, Lee HK,

38 Leeuwenburgh C, Lemieux H, Lenaz G, Lerfall J, Li PA, Liepins E, Liu J, Lucchinetti E, Macedo MP,

39 MacMillan-Crow LA, Makarova E, Makrecka-Kuka M, Malik AN, Markova M, Martin DS, Mazat JP,

40 McKenna HT, Menze MA, Merz T, Meszaros AT, Methner A, Michalak S, Moellering DR, Moisoi N,

41 Molina AJA, Montaigne D, Moore AL, Moreau K, Moreno-Sánchez R, Moreira BP, Mracek T,

42 Muntane J, Muntean DM, Murray AJ, Nair KS, Nehlin JO, Nemec M, Neufer PD, Neuzil J, Neviere

43 R, Newsom S, Nozickova K, O'Brien KA, O'Gorman D, Olgar Y, Oliveira MF, Oliveira MT, Oliveira

44 PF, Oliveira PJ, Orynbayeva Z, Osiewacz HD, Ounpuu L, Pak YK, Pallotta ML, Palmeira CM,

45 Parajuli N, Passos JF, Passrugger M, Patel HH, Pavlova N, Pecina P, Pelnena D, Pereira da Silva Grilo

46 da Silva F, Perez Valencia JA, Pesta D, Petit PX, Pettersen IKN, Pichaud N, Piel S, Pietka TA, Pino

47 MF, Pirkmajer S, Porter C, Porter RK, Pranger F, Prochownik EV, Pulinilkunnil T, Puskarich MA,

48 Puurand M, Quijano C, Radenkovic F, Radi R, Ramzan R, Rattan S, Reboredo P, Rich PR, Renner-

49 Sattler K, Rial E, Robinson MM, Roden M, Rodríguez-Enriquez S, Rohlena J, Rolo AP, Ropelle ER,

50 Røsland GV, Rossignol R, Rossiter HB, Rubelj I, Rybacka-Mossakowska J, Saada A, Safaei Z, Salin

51 K, Salvadego D, Sandi C, Sanz A, Sazanov LA, Scatena R, Schartner M, Scheibye-Knudsen M,

52 Schilling JM, Schlattner U, Schönfeld P, Schulz R, Schwarzer C, Scott GR, Shabalina IG, Sharma P,

53 Sharma V, Shevchuk I, Siewiera K, Silber AM, Silva AM, Sims CA, Singer D, Skolik R, Smenes BT,

54 Smith J, Soares FAA, Sobotka O, Sokolova I, Sonkar VK, Sowton AP, Sparagna GC, Sparks LM,

55 Spinazzi M, Stankova P, Starr J, Stary C, Stelfa G, Stiban J, Stier A, Stocker R, Sumbalova Z,

56 Suravajhala P, Svalbe B, Swerdlow RH, Swiniuch D, Szabo I, Szewczyk A, Szibor M, Tanaka M,

57 Tandler B, Tarnopolsky MA, Tausan D, Tavernarakis N, Tepp K, Thyfault JP, Tomar D, Towheed A,

58 Tretter L, Trifunovic A, Trivigno C, Tronstad KJ, Trougakos IP, Tuncay E, Turan B, Tyrrell DJ,

59 Urban T, Valentine JM, Vendelin M, Vercesi AE, Victor VM, Viel C, Vieyra A, Vilks K, Villena JA,

60 Vinogradov AD, Viscomi C, Vitorino RMP, Vogt S, Volani C, Volska K, Votion DM, Vujacic-Mirski

61 K, Wagner BA, Ward ML, Warnsmann V, Wasserman DH, Watala C, Wei YH, Wickert A,

62 Wieckowski MR, Williams C, Winwood-Smith H, Wohlgemuth SE, Wohlwend M, Wolff J, Wüst

63 RCI, Yokota T, Zablocki K, Zaugg K, Zaugg M, Zdrazilova L, Zhang Y, Zhang YZ, Zíková A,

64 Zischka H, Zorzano A, Zvejniece L

65

66 **Updates and discussion:**

67 <http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2018-02-08>

68

69 Correspondence: Gnaiger E

70 *Chair COST Action CA15203 MitoEAGLE –* [http://www.mitoeagle.org](http://www.mitoeagle.org/)

71 *Department of Visceral, Transplant and Thoracic Surgery, D. Swarovski Research Laboratory,*

72 *Medical University of Innsbruck, Innrain 66/4, A-6020 Innsbruck, Austria*

73 *Email:* mitoeagle@i-med.ac.at; *Tel: +43 512 566796, Fax: +43 512 566796 20*

74



75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

**Table of contents**

**Abstract**

**Executive summary**

**1. Introduction** – Box 1: In brief: Mitochondria and Bioblasts

**2. Coupling states and rates in mitochondrial preparations**

*2.1. Cellular and mitochondrial respiration*

2.1.1. Aerobic and anaerobic catabolism and ATP turnover

2.1.2. Specification of biochemical dose

*2.2. Mitochondrial preparations*

*2.3. Electron transfer pathways*

*2.4. Respiratory coupling control*

2.4.1. Coupling

2.4.2. Phosphorylation, P», and P»/O2 ratio

2.4.3. Uncoupling

*2.5. Coupling states and respiratory rates*

2.5.1. LEAK-state

2.5.2. OXPHOS-state

2.5.3. Electron transfer-state

2.5.4. ROX state and *Rox*

2.5.5. Quantitative relations

2.5.6. The steady-state

*2.6. Classical terminology for isolated mitochondria*

2.6.1. State 1

2.6.2. State 2

2.6.3. State 3

2.6.4. State 4

2.6.5. State 5

*2.7. Control and regulation*

**3. What is a rate?** – Box 2: Metabolic flows and fluxes: vectoral, vectorial, and scalar

**4. Normalization of rate per sample**

*4.1. Flow: per object*

4.1.1. Number concentration

4.1.2. Flow per object

*4.2. Size-specific flux: per sample size*

4.2.1. Sample concentration

4.2.2. Size-specific flux

*4.3. Marker-specific flux: per mitochondrial content*

4.3.1. Mitochondrial concentration and mitochondrial markers

4.3.2. mt-Marker-specific flux

**5. Normalization of rate per system**

*5.1. Flow: per chamber*

*5.2. Flux: per chamber volume*

5.2.1. System-spedific flux

5.2.2. Advancement per volume

**6. Conversion of units**

**7. Conclusions** – Box 3: Recommendations for studies with mitochondrial preparations

**References**

**Supplement**

S1. Manuscript phases and versions - an open-access approach

S2. Authors

S3. Joining COST Actions

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

**Abstract** As the knowledge base and importance of mitochondrial physiology to human health expands, the necessity for harmonizing the terminology concerning mitochondrial respiratory states and rates has become increasingly apparent. The chemiosmotic theory establishes the mechanism of energy transformation and coupling in oxidative phosphorylation. The unifying concept of the protonmotive force provides the framework for developing a consistent theoretical foundation of mitochondrial physiology and bioenergetics. We follow IUPAC guidelines on terminology in physical chemistry, extended by considerations of open systems and thermodynamics of irreversible processes. The concept-driven constructive terminology incorporates the meaning of each quantity and aligns concepts and symbols with the nomenclature of classical bioenergetics. We endeavour to provide a balanced view of mitochondrial respiratory control and a critical discussion on reporting data of mitochondrial respiration in terms of metabolic flows and fluxes. Uniform standards for evaluation of respiratory states and rates will ultimately contribute to reproducibility between laboratories and thus support the development of databases of mitochondrial respiratory function in species, tissues, and cells. Clarity of concept and consistency of nomenclature facilitate effective transdisciplinary communication, education, and ultimately further discovery.

*Keywords:* Mitochondrial respiratory control, coupling control, mitochondrial preparations, protonmotive force, uncoupling, oxidative phosphorylation: OXPHOS, efficiency, electron transfer: ET; electron transfer system: ETS, proton leak: LEAK, residual oxygen consumption: ROX, State 2, State

3, State 4, normalization, flow, flux, O2

**Executive summary**

In view of the broad implications for health care, mitochondrial researchers face an increasing responsibility to disseminate their fundamental knowledge and novel discoveries to a wide range of stakeholders and scientists beyond the group of specialists. This requires implementation of a commonly accepted terminology within the discipline and standardization in the translational context. Authors, reviewers, journal editors, and lecturers are challenged to collaborate with the aim to harmonize the nomenclature in the growing field of mitochondrial physiology and bioenergetics, from evolutionary biology and comparative physiology to mitochondrial medicine. In the present communication we focus on the following concepts in mitochondrial physiology:

1. Aerobic respiration depends on the coupling of phosphorylation (ADP → ATP) to O2 flux in catabolic reactions. Coupling in oxidative phosphorylation is mediated by the translocation of protons across the inner mitochondrial membrane through proton pumps generating or utilizing the protonmotive force that is maintained between the mitochondrial matrix and intermembrane compartment or outer mitochondrial space. Compartmental coupling distinguishes this vectorial component of oxidative phosphorylation from glycolytic fermentation as the counterpart of cellular core energy metabolism (**Figure 1**). Cell respiration is distinguished from fermentation: (*1*) Electron acceptors are supplied by external respiration for the maintenance of redox balance, whereas fermentation is characterized by an internal electron acceptor produced in intermediary metabolism. In aerobic cell respiration, redox balance is maintained by O2 as the electron acceptor. (*2*) Compartmental coupling in vectorial oxidative phosphorylation contrasts to exclusively scalar substrate-level phosphorylation in fermentation.

2. When measuring mitochondrial metabolism, the contribution of fermentation and other cytosolic interactions must be excluded from analysis by disrupting the barrier function of the plasma

membrane. Selective removal or permeabilization of the plasma membrane yields mitochondrial preparations—including isolated mitochondria, tissue and cellular

preparations—with structural and functional integrity. Subsequently, extra-mitochondrial concentrations of fuel substrates, ADP, ATP, inorganic phosphate, and cations including H+ can be controlled to determine mitochondrial function under a set of conditions defined as *coupling control states*. We strive to incorporate an easily recognized and understood concept- driven terminology of bioenergetics with explicit terms and symbols that define the nature of

respiratory states.

3. Mitochondrial coupling states are defined according to the control of respiratory oxygen flux by the protonmotive force. Capacities of oxidative phosphorylation and electron transfer are

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236


237

238

239

measured at kinetically saturating concentrations of fuel substrates, ADP and inorganic phosphate, and O2, or at optimal uncoupler concentrations, respectively, in the absence of Complex IV inhibitors such as NO, CO, or H2S. Respiratory capacity is a measure of the upper boundary of the rate of respiration; it depends on the substrate type undergoing oxidation, and provides reference values for the diagnosis of health and disease, and for evaluation of the effects of **E**volutionary background, **A**ge, **G**ender, **L**ifestyle, and **E**nvironment.

**Figure 1. Internal and external respiration** Mitochondrial respiration is the oxidation of fuel substrates (electron donors) and reduction of O2 catalysed by the electron transfer system, ETS: (**mt**) mitochondrial catabolic respiration; (**ce**) total cellular O2 consumption; and (**ext**) external respiration. All chemical reactions, r, that consume O2 in the cells of an organism, contribute to cell respiration, *J*rO2. In addition to mitochondrial catabolic respiration, O2 is consumed by:



 Mitochondrial residual O2 consumption, *Rox*.  Non-mitochondrial O2 consumption by catabolic reactions, particularly peroxisomal oxidases and microsomal

cytochrome P450 systems.  Non- mitochondrial *Rox* by reactions unrelated to catabolism.  Extracellular *Rox*.  Aerobic microbial respiration. Bars are not at a quantitative scale.

(mt) **Mitochondrial catabolic respiration**, *J*kO2, is the O2 consumption by the mitochondrial ETS excluding *Rox*.

(ce) **Cell respiration**, *J*rO2, takes into account

internal O2-consuming reactions, r, including catabolic respiration and *Rox*. Catabolic cell respiration is the O2 consumption associated with catabolic pathways in the cell, including mitochondrial

catabolism in addition to peroxisomal and microsomal oxidation reactions ().

(ext) **External respiration** balances internal respiration at steady-state, including extracellular *Rox* () and aerobic respiration by the microbiome (). O2 is transported from the environment across the respiratory cascade, *i.e.*, circulation between tissues and diffusion across cell membranes, to the intracellular compartment. The respiratory quotient, *RQ*, is the molar CO2/O2 exchange ratio; when combined with the respiratory nitrogen quotient, N/O2 (mol N given off per mol O2 consumed), the *RQ* reflects the proportion of carbohydrate, lipid and protein utilized in cell respiration during aerobically balanced steady-states. Bicarbonate and CO2 are transported in reverse to the extracellular mileu and the organismic environment. Hemoglobin provides the molecular paradigm for the combination of O2 and CO2 exchange, as do lungs and gills on the morphological level.

4. Incomplete tightness of coupling, *i.e.*, some degree of uncoupling relative to the substrate- dependent coupling stoichiometry, is a characteristic of energy-transformations across membranes. Uncoupling is caused by a variety of physiological, pathological, toxicological, pharmacological, and environmental conditions that exert an influence not only on the proton leak and cation cycling, but also on proton slip within the proton pumps and the structural integrity of the mitochondria. A more loosely coupled state is induced by stimulation of mitochondrial superoxide formation and the bypass of proton pumps. In addition, the use of protonophores represents an experimental uncoupling intervention to assess the transition from a well-coupled to a noncoupled state of mitochondrial respiration.

5. Respiratory oxygen consumption rates have to be carefully normalized to enable meta-analytic studies beyond the question of a particular experiment. Therefore, all raw data on rates and

variables for normalization should be published in an open access data repository.

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

Normalization of rates for: (*1*) the number of objects (cells, organisms); (*2*) the volume or mass of the experimental sample; and (*3*) the concentration of mitochondrial markers in the experimental chamber are sample-specific normalizations, which are distinguished from system-specific normalization for the volume of the chamber (the measuring system).

6. The consistent use of terms and symbols will facilitate transdisciplinary communication and support the further development of a collaborative database on bioenergetics and

mitochondrial physiology. The present considerations are focused on studies with

mitochondrial preparations. These will be extended in a series of reports on pathway control of mitochondrial respiration, respiratory states in intact cells, and harmonization of experimental procedures.

**Box 1: In brief – Mitochondria and Bioblasts**

‘*For the physiologist, mitochondria afforded the first opportunity for an experimental approach to structure-function relationships, in particular those involved in active*

*transport, vectorial metabolism, and metabolic control mechanisms on a subcellular level*’

(Ernster and Schatz 1981).

Mitochondria are oxygen-consuming electrochemical generators that evolved from the endosymbiotic alphaproteobacteria which became integrated into a host cell related to Asgard Archaea (Margulis 1970; Lane

2005; Roger *et al.* 2017). They were described by Richard Altmann (1894) as ‘bioblasts’, which include not only the mitochondria as presently defined, but also symbiotic and free-living bacteria. The word

‘mitochondria’ (Greek mitos: thread; chondros: granule) was introduced by Carl Benda (1898).

Contrary to current textbook dogma, mitochondria form dynamic networks within eukaryotic cells. Mitochondrial movement is supported by microtubules and morphology can change in response to energy requirements of the cell via processes known as fusion and fission; these interactions allow mitochondria to communicate within a network (Chan 2006). Mitochondria can even traverse cell boundaries in a process known as horizontal mitochondrial transfer (Torralba *et al.* 2016). Another defining characteristic of mitochondria is the double membrane. The mitochondrial inner membrane (mtIM) forms dynamic tubular to disk-shaped cristae that separate the mitochondrial matrix, *i.e*., the negatively charged internal mitochondrial compartment, from the intermembrane space; the latter being enclosed by the mitochondrial outer membrane (mtOM) and positively charged with respect to the matrix. The mtIM contains the non-bilayer phospholipid, cardiolipin, which is not present in any other eukaryotic cellular membrane. Cardiolipin has many regulatory functions (Oemer *et al.* 2018); in particular, it stabilizes and promotes the formation of respiratory supercomplexes (SC I*n*III*n*IV*n*), which are supramolecular assemblies based upon specific and dynamic interactions between individual respiratory complexes (Greggio *et al.* 2017; Lenaz *et al.* 2017). The mitochondrial membrane is plastic and exerts an influence on the functional properties of proteins incorporated in membranes (Waczulikova *et al.* 2007). Intracellular stress factors may cause shrinking or swelling of the mitochondrial matrix that can ultimately result in permeability transition.

Mitochondria are the structural and functional elementary components of cell respiration. Mitochondrial respiration is the reduction of molecular oxygen by electron transfer coupled to electrochemical proton translocation across the mtIM. In the process of oxidative phosphorylation (OXPHOS), the catabolic reaction of oxygen consumption is electrochemically coupled to the transformation of energy in the form of adenosine triphosphate (ATP; Mitchell 1961, 2011). Mitochondria are the powerhouses of the cell that contain the machinery of the OXPHOS-pathways, including transmembrane respiratory complexes (proton pumps with FMN, Fe-S and cytochrome *b*, *c*, *aa*3 redox systems); alternative dehydrogenases and oxidases; the coenzyme ubiquinone (Q); F-ATPase or ATP synthase; the enzymes of the tricarboxylic acid cycle (TCA), fatty acid and amino acid oxidation; transporters of ions, metabolites and co-factors; iron/sulphur cluster synthesis; and mitochondrial kinases related to catabolic pathways. The mitochondrial proteome comprises over 1,200 proteins (Calvo *et al.* 2015; 2017), mostly encoded by nuclear DNA (nDNA), with a variety of functions, many of which are relatively well known ,*e.g.,* proteins regulating mitochondrial biogenesis or apoptosis, while others are still under investigation, or need to be identified ,*e.g.,* permeability transition pore, alanine transporter. Only recently has it been possible to use the mammalian mitochondrial proteome to discover and characterize the genetic basis of mitochondrial diseases (Williams *et al.* 2016; Palmfeldt and Bross 2017).

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

Numerous cellular processes are orchestrated by a constant crosstalk between mitochondria and other cellular components. For example, the crosstalk between mitochondria and the endoplasmic reticulum is involved in the regulation of calcium homeostasis, cell division, autophagy, differentiation, and anti-viral signaling (Murley and Nunnari 2016). Mitochondria contribute to the formation of peroxisomes, which are hybrids of mitochondrial and ER-derived precursors (Sugiura *et al.* 2017). Cellular mitochondrial homeostasis (mitostasis) is maintained through regulation at transcriptional, post-translational, and epigenetic levels. Cell signalling modules contribute to homeostatic regulation throughout the cell cycle or even cell death by activating proteostatic modules ,*e.g.*, the ubiquitin- proteasome and autophagy-lysosome/vacuole pathways; specific proteases like LON, and genome stability modules in response to varying energy demands and stress cues (Quiros *et al.* 2016). Several post-translational modifications, including acetylation and bitrosylation, are also capable of influencing the bioenergetic response, with clinically significant implications for health and disease (Carrico *et al.*

2018).

Mitochondria of higher eukaryotes typically maintain several copies of their own circular genome known as mitochondrial DNA (mtDNA; hundred to thousands per cell; Cummins 1998), which is

maternally inherited in humans. Biparental mitochondrial inheritance is documented in other mammals, birds,

fish, reptiles and invertebrate groups, and is even the norm in some bivalve taxonomic groups (Breton

*et al.* 2007; White *et al.* 2008). The mitochondrial genome of the angiosperm *Amborella* contains a record of six mitochondrial genome equivalents aquired by horizontal transfer of entire genomes, two from angiosperms, three from algae and one from mosses (Rice *et al.* 2016). In unicellular organisms ,*i.e.*, protists, the structural organization of mitochondrial genomes is highly variable and includes circular and linear DNA (Zikova *et al.* 2016). While some of the free-living flagellates exhibit the largest known gene coding capacity ,e.g. jakobid *Andalucia godoyi* mitochondrial DNA codes for 106 genes (Burger *et al.* 2013), some protist groups,e.g. alveolates, possess mitochondrial genomes with only three protein-coding genes and two rRNAs (Feagin *et al.* 2012). The complete loss of mitochondrial genome is observed in highly reduced mitochondria of *Cryptosporidium* species (Liu *et al.* 2016). Reaching the final extreme, the microbial eukaryote, oxymonad *Monocercomonoides*, has no mitochondrion whatsoever and lacks all typical nuclear-encoded mitochondrial proteins, showing that while in 99% of organisms mitochondria play a vital role, this organelle is not indispensable (Karnkowska *et al.*

2016).

In vertebrates but not all invertebrates, mtDNA is compact (16.5 kB in humans) and encodes 13 protein subunits of the transmembrane respiratory Complexes CI, CIII, CIV and ATP synthase (F-

ATPase), 22 tRNAs, and two RNAs. Additional gene content has been suggested to include microRNAs, piRNA, smithRNAs, repeat associated RNA, and even additional proteins (Duarte *et al.* 2014; Lee *et*

*al.* 2015; Cobb *et al.* 2016). The mitochondrial genome requires nuclear-encoded mitochondrially targeted proteins, *e.g.*, TFAM, for its maintenance and expression (Rackham *et al.* 2012). Both genomes

encode peptides of the membrane spanning redox pumps (CI, CIII and CIV) and F-ATPase, leading to strong constraints in the coevolution of both genomes (Blier *et al.* 2001).

Given the multiple roles of mitochondria, it is perhaps not surprising that mitochondrial

dysfunction is associated with a wide variety of genetic and degenerative diseases. Robust mitochondrial function is supported by physical exercise and caloric balance, and is central for sustained metabolic health throughout life. Therefore, a more consistent set of definitions for mitochondrial physiology will increase our understanding of the etiology of disease and improve the diagnostic repertoire of mitochondrial medicine with a focus on protective medicine, lifestyle, and healthy aging.

Mitochondrion is singular and mitochondria is plural. Abbreviation: mt, as generally used in mtDNA.

**1. Introduction**

Mitochondria are the powerhouses of the cell with numerous physiological, molecular, and genetic functions (**Box 1**). Every study of mitochondrial health and disease faces **E**volution, **A**ge, **G**ender, **L**ifestyle, and **E**nvironment (MitoEAGLE) as essential background conditions intrinsic to the individual person or cohort, species, tissue, and to some extent even cell line. As a large and coordinated group of laboratories and researchers, the mission of the global MitoEAGLE Network is to

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

generate the necessary scale, type, and quality of consistent data sets and conditions to address this intrinsic complexity. Harmonization of experimental protocols and implementation of a quality control and data management system are required to interrelate results gathered across a spectrum of studies and to generate a rigorously monitored database focused on mitochondrial respiratory function. In this way, researchers from a variety of disciplines can compare their findings using clearly defined and accepted international standards.

With an emphasis on quality of research, published data can be useful far beyond the specific question of a particular experiment. For example, collaborative data sets support the development of

open-access databases such as those for National Institutes of Health sponsored research in genetics,

proteomics, and metabolomics. Indeed, enabling meta-analysis is the most economic way of providing robust answers to biological questions (Cooper *et al.* 2009). However, the reproducibility of quantitative results and databases depends on accurate measurements under strictly-defined conditions. Likewise, meaningful interpretation and comparability of experimental outcomes requires standardisation of protocols between research groups at different institutes. In addition to quality control, a conceptual framework is also required to standardise and homogenise terminology and methodology. Vague or ambiguous jargon can lead to confusion and may convert valuable signals to wasteful noise. For this reason, measured values must be expressed in standard units for each parameter used to define mitochondrial respiratory function. A consensus on fundamental nomenclature and conceptual coherence, however, is missing in the expanding field of mitochondrial physiology. To fill this gap, the present communication provides an in-depth review on harmonization of nomenclature and definition of technical terms, which are essential to improve the awareness of the intricate meaning of current and past scientific vocabulary. This is important for documentation and integration into databases in general, and quantitative modelling in particular (Beard 2005).

In this review, we focus on coupling states and fluxes through metabolic pathways of aerobic energy transformation in mitochondrial preparations as a first step in the attempt to generate a

conceptually-oriented nomenclature in bioenergetics and mitochondrial physiology. Respiratory control

by fuel substrates and specific inhibitors of respiratory enzymes, coupling states of intact cells, and respiratory flux control ratios will be reviewed in subsequent communications, prepared in the frame of

COST Action MitoEAGLE open to global bottom-up input.

**2. Coupling states and rates in mitochondrial preparations**

‘*Every professional group develops its own technical jargon for talking about matters of critical concern ... People who know a word can share that idea with other members of their group, and*

*a shared vocabulary is part of the glue that holds people together and allows them to create a*

*shared culture*’ (Miller 1991).

*2.1. Cellular and mitochondrial respiration*

**2.1.1. Aerobic and anaerobic catabolism and ATP turnover:** In respiration, electron transfer is coupled to the phosphorylation of ADP to ATP, with energy transformation mediated by the protonmotive force, ∆*p* (**Figure 2**). Anabolic reactions are coupled to catabolism, both by ATP as the intermediary energy currency and by small organic precursor molecules as building blocks for biosynthesis. Glycolysis involves substrate-level phosphorylation of ADP to ATP in fermentation without utilization of O2, studied mainly in intact cells and organisms. Many cellular fuel substrates are catabolized to acetyl-CoA or to glutamate, and further electron transfer reduces nicotinamide adenine dinucleotide to NADH or flavin adenine dinucleotide to FADH2. Subsequent mitochondrial electron transfer to O2 is coupled to proton translocation for the control of ∆*p* and phosphorylation of ADP (**Figure 2B and 2C**). In contrast, extra-mitochondrial oxidation of fatty acids and amino acids proceeds partially in peroxisomes without coupling to ATP production: acyl-CoA oxidase catalyzes the oxidation of FADH2 with electron transfer to O2; amino acid oxidases oxidize flavin mononucleotide FMNH2 or FADH2 (**Figure 2A**).

404

405

406

407

408


409

410

411

412

**Figure 2. Cell respiration and oxidative phosphorylation (OXPHOS)**



Mitochondrial respiration is the oxidation of fuel substrates (electron donors) with electron transfer to O2 as the electron acceptor. For explanation of symbols see also **Figure 1**.

**(A)** Respiration of intact cells: Extra-mitochondrial catabolism of macrofuels and uptake

of small molecules by the cell provide the mitochondrial fuel substrates. Dashed arrows indicate the connection between the redox proton pumps (respiratory Complexes CI, CIII and CIV) and the transmembrane ∆*p*. Coenzyme Q (Q) and the cytochromes *b*, *c*, and *aa*3 are redox systems of the mitochondrial inner membrane, mtIM. Glycerol-3-phosphate, Gp.

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

**(B)** Respiration in mitochondrial preparations: The mitochondrial electron transfer system (ETS) is (*1*) fuelled by diffusion and transport of substrates across the mtOM and mtIM, and in addition consists of the (*2*) matrix-ETS, and (*3*) membrane-ETS. Electron transfer converges at the N-junction, and from CI, CII, and electron transferring flavoprotein complex (CETF) at the Q-junction. Unlabeled arrows converging at the Q-junction indicate additional ETS-sections with electron entry into Q through glycerophosphate dehydrogenase, dihydro-orotate dehydrogenase, proline dehydrogenase, choline dehydrogenase, and sulfide-ubiquinone oxidoreductase. The dotted arrow indicates the branched pathway of oxygen consumption by alternative quinol oxidase (AOX). ET- pathways are coupled to the phosphorylation-pathway. The H+pos/O2 ratio is the outward proton flux from the matrix space to the positively (pos) charged vesicular compartment, divided by catabolic O2 flux in the NADH-pathway. The H+neg/P» ratio is the inward proton flux from the inter-membrane space to the negatively (neg) charged matrix space, divided by the flux of phosphorylation of ADP to ATP. These stoichiometries are not fixed because of ion leaks and proton slip. Modified from Lemieux *et al*. (2017) and Rich (2013).

**(C)** OXPHOS coupling: O2 flux through the catabolic ET-pathway, *J*kO2, is coupled by the H+ circuit to flux through the phosphorylation-pathway of ADP to ATP, *J*P». **(D)** Chemiosmotic phosphorylation-pathway catalyzed by the proton pump F1FO•ATPase (F-ATPase, ATP synthase), adenine nucleotide translocase (ANT), and inorganic phosphate carrier (PiC). The H+neg/P» stoichiometry is the sum of the coupling stoichiometry in the F-ATPase reaction (•2.7 H+pos from the positive intermembrane space,

2.7 H+neg to the matrix, *i.e.*, the negative compartment) and the proton balance in the

2-

435

436

translocation of ADP3•, ATP4- ,and Pi

. Modified from Gnaiger (2014).

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

The plasma membrane separates the intracellular compartment including the cytosol, nucleus, and organelles from the extracellular environment. The plasma membrane consists of a lipid bilayer with embedded proteins and attached organic molecules that collectively control the selective permeability of ions, organic molecules, and particles across the cell boundary. The intact plasma membrane prevents the passage of many water-soluble mitochondrial substrates and inorganic ions—such as succinate, adenosine diphosphate (ADP) and inorganic phosphate (Pi) that must be precisely controlled at kinetically-saturating concentrations for the analysis of mitochondrial respiratory capacities. Respiratory capacities delineate, comparable to channel capacity in information theory (Schneider

2006), the upper boundary of the rate of O2 consumption measured in defined respiratory states. Despite the activity of solute carriers, *e.g.*, SLC13A3 and SLC20A2, which transport specific metabolites across

the plasma membrane of various cell types, the intact plasma membrane limits the scope of investigations into mitochondrial respiratory function in intact cells.

**2.1.2. Specification of biochemical dose:** Substrates, uncouplers, inhibitors, and other chemical reagents are titrated to analyse cellular and mitochondrial function. Nominal concentrations of these substances are usually reported as initial amount of substance concentration [mol∙L-1] in the incubation medium. When aiming at the measurement of kinetically saturated processes—such as OXPHOS- capacities the concentrations for substrates can be chosen according to the apparent equilibrium

constant, *K*m’. In the case of hyperbolic kinetics, only 80% of maximum respiratory capacity is obtained at a substrate concentration of four times the *K*m’, whereas substrate concentrations of 5, 9, 19 and 49 times the *K*m’ are theoretically required for reaching 83%, 90%, 95% or 98% of the maximal rate (Gnaiger 2001). Other reagents are chosen to inhibit or alter a particular process. The amount of these chemicals in an experimental incubation is selected to maximize effect, avoiding unacceptable off-target consequences that would adversely affect the data being sought. Specifying the amount of substance in an incubation as nominal concentration in the aqueous incubation medium can be ambiguous (Doskey *et al*. 2015), particularly for cations [TPP+, fluorescent dyes such as safranin, TMRM (Chowdhury *et al.*

2015)] and lipophilic substances [oligomycin, uncouplers, permeabilization agents (Doerrier *et al.* 2018)], which accumulate in the mitochondrial matrix or in biological membranes, respectively. Generally,

dose/exposure can be specified per unit of biological sample, *i.e.*, (nominal moles of xenobiotic)/(number of cells) [mol∙cell•1] or, as appropriate, per mass of biological sample [mol∙kg-1]. This approach to specification of dose/exposure provides a scalable parameter that can be used to design experiments, help interpret a wide variety of experimental results, and provide absolute information that allows researchers worldwide to make the most use of published data (Doskey *et al.* 2015).

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

*2.2. Mitochondrial preparations*

Mitochondrial preparations are defined as either isolated mitochondria or tissue and cellular preparations in which the barrier function of the plasma membrane is disrupted. Since this entails the loss of cell viability, mitochondrial preparations are not studied *in vivo*. In contrast to isolated mitochondria and tissue homogenate preparations, mitochondria in permeabilized tissues and cells are *in situ* relative to the plasma membrane. When studying mitochondrial preparations, substrate- uncoupler-inhibitor-titration (SUIT) protocols are used to establish respiratory coupling control states (CCS) and pathway control states (PCS) that provide reference values for various output variables (**Table 1**). Physiological conditions *in vivo* deviate from these experimentally obtained states; this is because kinetically-saturating concentrations, *e.g.,* of ADP, oxygen (O2; dioxygen) or fuel substrates, may not apply to physiological intracellular conditions. Further information is obtained in studies of kinetic responses to variations in fuel substrate concentrations, [ADP], or [O2] in the range between kinetically-saturating concentrations and anoxia (Gnaiger 2001).

The cholesterol content of the plasma membrane is high compared to mitochondrial membranes (Korn 1969). Therefore, mild detergents—such as digitonin and saponin—can be applied to selectively permeabilize the plasma membrane via interaction with cholesterol; this allows free exchange of organic molecules and inorganic ions between the cytosol and the immediate cell environment, while maintaining the integrity and localization of organelles, cytoskeleton, and the nucleus. Application of permeabilization agents (mild detergents or toxins) leads to washout of cytosolic marker enzymes— such as lactate dehydrogenase—and results in the complete loss of cell viability (tested by nuclear staining using plasma membrane-impermeable dyes), while mitochondrial function remains intact (tested by cytochrome *c* stimulation of respiration). Digitonin concentrations have to be optimized according to cell type, particularly since mitochondria from cancer cells contain significantly higher contents of cholesterol in both membranes (Baggetto and Testa-Perussini, 1990). For example, a dose of digitonin of 8 fmol∙cell•1 (10 pg∙cell•1; 10 µg∙10•6 cells) is optimal for permeabilization of endothelial cells, and the concentration in the incubation medium has to be adjusted according to the cell density (Doerrier *et al.* 2018). Respiration of isolated mitochondria remains unaltered after the addition of low concentrations of digitonin or saponin. In addition to mechanical cell disruption during homogenization of tissue, permeabilization agents may be applied to ensure permeabilization of all cells in tissue homogenates.

Suspensions of cells permeabilized in the respiration chamber and crude tissue homogenates contain all components of the cell at highly dilute concentrations. All mitochondria are retained in

chemically-permeabilized mitochondrial preparations and crude tissue homogenates. In the preparation

of isolated mitochondria, however, the mitochondria are separated from other cell fractions and purified by differential centrifugation, entailing the loss of mitochondria at typical recoveries ranging from 30% to 80% of total mitochondrial content (Lai *et al.* 2018). Using Percoll or sucrose density gradients to maximize the purity of isolated mitochondria may compromise the mitochondrial yield or structural and functional integrity. Therefore, mitochondrial isolation protocols need to be optimized according to each study. The term, *mitochondrial preparation*, neither includes intact cells, nor submitochondrial particles and further fractionation of mitochondrial components.

*2.3. Electron transfer pathways*

Mitochondrial electron transfer (ET) pathways are fuelled by diffusion and transport of substrates across the mtOM and mtIM. In addition, the mitochondrial electron transfer system (ETS) consists of the matrix-ETS and membrane-ETS (**Figure 2B**). Upstream sections of ET-pathways converge at the NADH-junction (N-junction). NADH is mainly generated in the tricarboxylic acid (TCA) cycle and is oxidized by Complex I (CI), with further electron entry into the coenzyme Q-junction (Q-junction). Similarly, succinate is formed in the TCA cycle and oxidized by CII to fumarate. CII is part of both the TCA cycle and the ETS, and reduces FAD to FADH2 with further reduction of ubiquinone to ubiquinol downstream of the TCA cycle in the Q-junction. Thus FADH2 is not a substrate but is the product of CII, in contrast to erroneous metabolic maps shown in many publications. β-oxidation of fatty acids (FA) generates FADH2 as the substrate of electron transferring flavoprotein complex (CETF).

Selected mitochondrial catabolic pathways, k, of electron transfer from the oxidation of fuel substrates to the reduction of O2 are activated by depletion of endogenous substrates and addition of fuel

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

5634

substrates to the mitochondrial respiration medium (**Figure 2B**). Substrate combinations and specific inhibitors of ET-pathway enzymes are used to obtain defined pathway control states in mitochondrial preparations (Gnaiger 2014).

*2.4. Respiratory coupling control*

**2.4.1. Coupling:** In mitochondrial electron transfer, vectorial transmembrane proton flux is coupled through the redox proton pumps CI, CIII, and CIV to the catabolic flux of scalar reactions, collectively measured as O2 flux, *J*kO2 (**Figure 2**). Thus mitochondria are elementary components of energy transformation. Energy is a conserved quantity and cannot be lost or produced in any internal process (First Law of Thermodynamics). Open and closed systems can gain or lose energy only by external fluxes—by exchange with the environment. Therefore, energy can neither be produced by mitochondria, nor is there any internal process without energy conservation. Exergy or Gibbs energy (‘free energy’) is the part of energy that can potentially be transformed into work under conditions of constant temperature and pressure. *Coupling* is the interaction of an exergonic process (spontaneous, negative exergy change) with an endergonic process (positive exergy change) in energy transformations which conserve part of the exergy that would be irreversibly lost or dissipated in an uncoupled process.

Pathway control states (PCS) and coupling control states (CCS) are complementary, since mitochondrial preparations depend on (*1*) an exogenous supply of pathway-specific fuel substrates and oxygen, and (*2*) exogenous control of phosphorylation (**Figure 2**).

**2.4.2. Phosphorylation, P», and P»/O2 ratio:** Phosphorylation in the context of OXPHOS is defined as phosphorylation of ADP by Pi to form ATP. On the other hand, the term phosphorylation is used generally in many contexts, *e.g.,* protein phosphorylation. This justifies consideration of a symbol

more discriminating and specific than P as used in the P/O ratio (phosphate to atomic oxygen ratio), where P indicates phosphorylation of ADP to ATP or GDP to GTP (**Figure 2**). We propose the symbol

P» for the endergonic (uphill) direction of phosphorylation ADP→ATP, and likewise the symbol P« for

the corresponding exergonic (downhill) hydrolysis ATP→ADP. P» refers mainly to electrontransfer phosphorylation but may also involve substrate-level phosphorylation as part of the TCA cycle

(succinyl-CoA ligase, phosphoglycerate kinase) and phosphorylation of ADP catalyzed by pyruvate

kinase, and of GDP phosphorylated by phosphoenolpyruvate carboxykinase. Transphosphorylation is performed by adenylate kinase, creatine kinase (mtCK), hexokinase, and nucleoside diphosphate kinase. In isolated mammalian mitochondria, ATP production catalyzed by adenylate kinase (2 ADP ↔ ATP + AMP) proceeds without fuel substrates in the presence of ADP (Komlódi and Tretter 2017). Kinase cycles are involved in intracellular energy transfer and signal transduction for regulation of energy flux.

The P»/O2 ratio (P»/4 e-) is two times the ‘P/O’ ratio (P»/2 e-) of classical bioenergetics. P»/O2 is a generalized symbol, not specific for determination of Pi consumption (Pi/O2 flux ratio), ADP depletion

(ADP/O2 flux ratio), or ATP production (ATP/O2 flux ratio). The mechanistic P»/O2 ratio—or P»/O2

stoichiometry—is calculated from the proton–to–O2 and proton–to–phosphorylation coupling stoichiometries (**Figure 2B**):

+

H /O

pos 2

neg

565

566

P»/O2 =

H+ /P» (1)

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

The H+pos/O2 coupling stoichiometry (referring to the full four electron reduction of O2) depends on the relative involvement of the three coupling sites (respiratory Complexes CI, CIII, and CIV) in the

catabolic ET-pathway from reduced fuel substrates (electron donors) to the reduction of O2 (electron acceptor). This varies with: (*1*) a bypass of CI by single or multiple electron input into the Q-junction;

and (*2*) a bypass of CIV by involvement of alternative oxidases, AOX, both of which are not expressed in mammalian mitochondria.

The H+pos/O2 coupling stoichiometry equals 12 in the ET-pathways involving CIII and CIV as proton pumps, increasing to 20 for the NADH-pathway through CI (**Figure 2B**), but a general consensus


on H+pos/O2 stoichiometries remains to be reached (Hinkle 2005; Wikström and Hummer 2012; Sazanov

2015). The H+neg/P» coupling stoichiometry (3.7; **Figure 2B**) is the sum of 2.7 H+neg required by the F- ATPase of vertebrate and most invertebrate species (Watt *et al.* 2010) and the proton balance in the

translocation of ADP, ATP and Pi (**Figure 2C**). Taken together, the mechanistic P»/O2 ratio is calculated at 5.4 and 3.3 for NADH- and succinate-linked respiration, respectively (Eq. 1). The corresponding

classical P»/O ratios (referring to the 2 electron reduction of 0.5 O2) are 2.7 and 1.6 (Watt *et al.* 2010), in agreement with the measured P»/O ratio for succinate of 1.58 ± 0.02 (Gnaiger *et al.* 2000).

582



583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

**Figure 3. Mechanisms of respiratory uncoupling**

An intact mitochondrial inner membrane, mtIM, is required for vectorial, compartmental coupling.

‘Acoupled’ respiration is the consequence of structural disruption with catalytic activity of non- compartmental mitochondrial fragments. Inducible uncoupling ,*e.g.*, by activation of UCP1, increases LEAK respiration; experimentally noncoupled respiration provides an estimate of ET-capacity obtained by titration of protonophores stimulating respiration to maximum O2 flux. H+ leak-uncoupled, decoupled, and loosely coupled respiration are components of intrinsic uncoupling (**Table 2**). Pathological dysfunction may affect all types of uncoupling, including permeability transition, causing intrinsically dyscoupled respiration. Similarly, toxicological and environmental stress factors can cause extrinsically dyscoupled respiration. Reduced fuel substrates, red; oxidized products, ox.

**2.4.3. Uncoupling:** The effective P»/O2 flux ratio (*Y*P»/O2 = *J*P»/*J*kO2) is diminished relative to the mechanistic P»/O2 ratio by intrinsic and extrinsic uncoupling or dyscoupling (**Figure 3**). Such generalized uncoupling is different from switching to mitochondrial pathways that involve fewer than three proton pumps (‘coupling sites’: Complexes CI, CIII, and CIV), bypassing CI through multiple electron entries into the Q-junction, or CIII and CIV through AOX (**Figure 2B**). Reprogramming of mitochondrial pathways leading to different types of substrates being oxidized may be considered as a switch of gears (changing the stoichiometry by altering the substrate that is oxidized) rather than uncoupling (loosening the tightness of coupling relative to a fixed stoichiometry). In addition, *Y*P»/O2 depends on several experimental conditions of flux control, increasing as a hyperbolic function of [ADP] to a maximum value (Gnaiger 2001).

Uncoupling of mitochondrial respiration is a general term comprising diverse mechanisms:

1. Proton leak across the mtIM from the pos– to the neg–compartment (H+ leak-uncoupled; **Figure**

**3**).

2. Cycling of other cations, strongly stimulated by permeability transition; comparable to the use of protonophores, cation cycling is experimentally induced by valinomycin in the presence of K+;

3. Decoupling by proton slip in the redox proton pumps when protons are effectively not pumped

(CI, CIII, and CIV) or are not driving phosphorylation (F-ATPase);

4. Loss of vesicular (compartmental) integrity when electron transfer is acoupled;

•–

614

615

5. Electron leak in the loosely coupled univalent reduction of O2 to superoxide (O2

anion radical).

; superoxide

616

617

Differences of terms—uncoupled *vs.* noncoupled—are easily overlooked, although they relate to different meanings of uncoupling (**Figure 3** and **Table 2**).

618

619

620

621

622

623

624

625

626

627

628

629

630

631

*2.5. Coupling states and respiratory rates*

To extend the classical nomenclature on mitochondrial coupling states (Section 2.6) by a concept- driven terminology that explicitly incorporates information on the meaning of respiratory states, the terminology must be general and not restricted to any particular experimental protocol or mitochondrial preparation (Gnaiger 2009). Concept-driven nomenclature aims at mapping the meaning and concept behind the words and acronyms onto the forms of words and acronyms (Miller 1991). The focus of concept-driven nomenclature is primarily the conceptual *why*, along with clarification of the experimental *how*.

**Table 1. Coupling states and residual oxygen consumption in mitochondrial preparations in relation to respiration- and phosphorylation-flux, *J*kO2 and *J*P», and protonmotive force, ∆*p*.** Coupling states are established at kinetically-saturating concentrations of fuel substrates and O2.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **State** | ***J*kO2** | ***J*P»** | **∆*p*** | **Inducing factors** | **Limiting factors** |
| LEAK | *L*; low, cation leak- dependent respiration | 0 | max. | back-flux of cations including proton leak, proton slip | *J*P» = 0: (*1*) without ADP, *L*N; (*2*) max. ATP/ADP ratio, *L*T; or (*3*) inhibition of the phosphorylation- pathway, *L*Omy |
| OXPHOS | *P*; high, ADP- stimulated respiration, OXPHOS-capacity | max. | high | kinetically- saturating [ADP] and [Pi] | *J*P» by phosphorylation- pathway; or *J*kO2 by ET- capacity |
| ET | *E*; max., noncoupled respiration, ET-capacity | 0 | low | optimal external uncoupler concentration for max. *J*O2,*E* | *J*kO2 by ET-capacity |
| ROX | *Rox*; min., residual  O2 consumption | 0 | 0 | *J*O2,*Rox* in non-ET- pathway oxidation reactions | inhibition of all ET- pathways; or absence of fuel substrates |

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

To provide a diagnostic reference for respiratory capacities of core energy metabolism, the capacity of oxidative phosphorylation, OXPHOS, is measured at kinetically-saturating concentrations of ADP and Pi. The oxidative ET-capacity reveals the limitation of OXPHOS-capacity mediated by the phosphorylation-pathway. The ET- and phosphorylation-pathways comprise coupled segments of the OXPHOS-system. By application of external uncouplers, ET-capacity is measured as noncoupled respiration. The contribution of intrinsically uncoupled O2 consumption is studied by preventing the stimulation of phosphorylation either in the absence of ADP or by inhibition of the phosphorylation- pathway. The corresponding states are collectively classified as LEAK-states when O2 consumption compensates mainly for ion leaks, including the proton leak. Defined coupling states are induced by: (*1*) adding cation chelators such as EGTA, binding free Ca2+ and thus limiting cation cycling; (*2*) adding ADP and Pi; (*3*) inhibiting the phosphorylation-pathway; and (*4*) uncoupler titrations, while maintaining a defined ET-pathway state with constant fuel substrates and inhibitors of specific branches of the ET- pathway.

The three coupling states, ET, LEAK and OXPHOS, are shown schematically with the corresponding respiratory rates, abbreviated as *E*, *L* and *P*, respectively (**Figure 4**). We distinguish

metabolic *pathways* from metabolic *states* and the corresponding metabolic *rates*; for example: ET-

pathways, ET-states, and ET-capacities, *E*, respectively (**Table 1**). The protonmotive force is *high* in the OXPHOS-state when it drives phosphorylation, *maximum* in the LEAK-state of coupled mitochondria, driven by LEAK-respiration at a minimum back-flux of cations to the matrix side, and *very low* in the ET-state when uncouplers short-circuit the proton cycle (**Table 1**).

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674


675

676

677

**Figure 4. Four-compartment model of oxidative phosphorylation**

Respiratory states (ET, OXPHOS, LEAK; **Table 1**) and corresponding



rates (*E, P, L*) are connected by the



protonmotive force, ∆*p*. (*1*) ET- capacity, *E*, is partitioned into (*2*)

dissipative LEAK-respiration, *L*,

when the Gibbs energy change of catabolic O2 flux is irreversibly lost, (*3*) net OXPHOS-capacity, *P-L*, with

partial conservation of the capacity to perform work, and (*4*) the excess capacity, *E-P*. Modified from

Gnaiger (2014).



**Figure 5. Respiratory coupling**

**states**

**(A) LEAK-state and rate,** *L***:** Oxidation only, since phosphorylation is arrested, *J*P» = 0, and catabolic O2 flux, *J*kO2,*L*, is controlled mainly by the proton leak and slip, *J*mH+neg, at maximum protonmotive force (**Figure**

**4**). Extramitochondrial ATP may be hydrolyzed by extramitochondrial ATPases, *J*P«; then phosphorylation must be blocked.

**(B) OXPHOS-state and rate,** *P***:** Oxidation coupled to phosphorylation, *J*P», which is stimulated by kinetically-saturating [ADP] and [Pi], supported by a high protonmotive force. O2 flux, *J*kO2,*P*, is well-coupled at a P»/O2 ratio of *J*P»,*P*/*J*O2,*P*. Extramitochondrial ATPases may recycle ATP, *J*P«.

**(C) ET-state and rate,** *E***:** Oxidation only, since phosphorylation is zero,

*J*P» = 0, at optimum exogenous uncoupler concentration when

noncoupled respiration, *J*kO2,*E*, is maximum. The F-ATPase may hydrolyze extramitochondrial ATP.

**2.5.1. LEAK-state** (**Figure 5A**): The LEAK-state is defined as a state of mitochondrial respiration when O2 flux mainly compensates for ion leaks in the absence of ATP synthesis, at kinetically-saturating concentrations of O2, respiratory fuel substrates, and Pi. LEAK-respiration is measured to obtain an estimate of intrinsic uncoupling without addition of an experimental uncoupler: (*1*) in the absence of adenylates, *i.e.*, AMP, ADP and ATP; (*2*) after depletion of ADP at a maximum ATP/ADP ratio; or (*3*) after inhibition of the phosphorylation-pathway by inhibitors of F-ATPase—such as oligomycin, or of adenine nucleotide translocase—such as carboxyatractyloside. Adjustment of the nominal concentration of these inhibitors to the density of biological sample applied can minimize or avoid inhibitory side-effects exerted on ET-capacity or even some dyscoupling.

678

**Table 2. Terms on respiratory coupling and uncoupling.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Term** | ***J*kO2** | **P»/O2** | **Notes** |
| acoupled |  | 0 | electron transfer in mitochondrial fragments without vectorial proton translocation (**Figure 3**) |

uncoupled *L* 0 non-phosphorylating LEAK-respiration (**Figure 5A**)



intrinsic, no protonophore added

proton leak- uncoupled

0 component of *L*, H+ diffusion across the mtIM (**Figure**

**3**)

decoupled 0 component of *L*, proton slip (**Figure 3**)

loosely coupled

0 component of *L*, lower coupling due to superoxide formation and bypass of proton pumps by electron leak (**Figure 3**)

dyscoupled 0 pathologically, toxicologically, environmentally increased uncoupling, mitochondrial dysfunction

inducibly uncoupled

0 by UCP1 or cation (*e.g.,* Ca2+) cycling (**Figure 3**)

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

noncoupled *E* 0 ET-capacity, non-phosphorylating respiration stimulated to maximum flux at optimum exogenous uncoupler concentration (**Figure 5C**)

well-coupled *P* high OXPHOS-capacity, phosphorylating respiration with an intrinsic LEAK component (**Figure 5B**)

fully coupled *P – L* max. OXPHOS-capacity corrected for LEAK-respiration

(**Figure 4**)

• **Proton leak and uncoupled respiration:** The intrinsic proton leak is the *uncoupled* leak current of protons in which protons diffuse across the mtIM in the dissipative direction of the downhill protonmotive force without coupling to phosphorylation (**Figure 5A**). The proton leak flux depends non-linearly on the protonmotive force (Garlid *et al.* 1989; Divakaruni and Brand 2011), which is a temperature-dependent property of the mtIM and may be enhanced due to possible contamination by free fatty acids. Inducible uncoupling mediated by uncoupling protein 1 (UCP1) is physiologically controlled, *e.g.*, in brown adipose tissue. UCP1 is a member of the mitochondrial carrier family that is involved in the translocation of protons across the mtIM (Klingenberg 2017). Consequently, this short-circuit lowers the protonmotive force and stimulates electron transfer, respiration, and heat dissipation in the absence of phosphorylation of ADP.

• **Cation cycling:** There can be other cation contributors to leak current including calcium and probably magnesium. Calcium influx is balanced by mitochondrial Na+/Ca2+ or H+/Ca2+ exchange, which is balanced by Na+/H+ or K+/H+ exchanges. This is another effective uncoupling mechanism different from proton leak (**Table 2**).

• **Proton slip and decoupled respiration:** Proton slip is the *decoupled* process in which protons are only partially translocated by a redox proton pump of the ET-pathways and slip back to the original vesicular compartment. The proton leak is the dominant contributor to the overall leak current in mammalian mitochondria incubated under physiological conditions at 37 °C, whereas proton slip increases at lower experimental temperature (Canton *et al.* 1995). Proton slip can also happen in association with the F-ATPase, in which the proton slips downhill across the pump to the matrix without contributing to ATP synthesis. In each case, proton slip is a property of the proton pump and increases with the pump turnover rate.

• **Electron leak and loosely coupled respiration**: Superoxide production by the ETS leads to a bypass of redox proton pumps and correspondingly lower P»/O2 ratio. This depends on the actual site of electron leak and the scavenging of hydrogen peroxide by cytochrome *c*, whereby electrons may re-enter the ETS with proton translocation by CIV.

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

• **Loss of compartmental integrity and acoupled respiration:** Electron transfer and catabolic O2 flux proceed without compartmental proton translocation in disrupted mitochondrial fragments. Such fragments are an artefact of mitochondrial isolation, and may not fully fuse to re-establish structurally intact mitochondria. Loss of mtIM integrity, therefore, is the cause of acoupled respiration, which is a nonvectorial dissipative process without control by the protonmotive force.

• **Dyscoupled respiration:** Mitochondrial injuries may lead to *dyscoupling* as a pathological or toxicological cause of *uncoupled* respiration. Dyscoupling may involve any type of uncoupling mechanism, *e.g.*, opening the permeability transition pore. Dyscoupled respiration is distinguished from the experimentally induced *noncoupled* respiration in the ET-state (**Table 2**).

**2.5.2. OXPHOS-state** (**Figure 5B**): The OXPHOS-state is defined as the respiratory state with kinetically-saturating concentrations of O2, respiratory, and phosphorylation substrates, and absence of exogenous uncoupler, which provides an estimate of the maximal respiratory capacity in the OXPHOS- state for any given ET-pathway state. Respiratory capacities at kinetically-saturating substrate concentrations provide reference values or upper limits of performance, aiming at the generation of data sets for comparative purposes. Physiological activities and effects of substrate kinetics can be evaluated relative to the OXPHOS-capacity.

As discussed previously, 0.2 mM ADP does not fully saturate flux in isolated mitochondria

(Gnaiger 2001; Puchowicz *et al.* 2004); greater [ADP] is required, particularly in permeabilized muscle fibres and cardiomyocytes, to overcome limitations by intracellular diffusion and by the reduced

conductance of the mtOM (Jepihhina *et al.* 2011; Illaste *et al.* 2012; Simson *et al*. 2016), either through

interaction with tubulin (Rostovtseva *et al.* 2008) or other intracellular structures (Birkedal *et al*. 2014). In addition, saturating ADP concentrations need to be evaluated under different experimental conditions such as temperature (Lemieux *et al.* 2017) and with different animal models (Blier and Guderley, 1993). In permeabilized muscle fibre bundles of high respiratory capacity, the apparent *K*m for ADP increases up to 0.5 mM (Saks *et al.* 1998), consistent with experimental evidence that >90% saturation is reached only at >5 mM ADP (Pesta and Gnaiger 2012). Similar ADP concentrations are also required for accurate determination of OXPHOS-capacity in human clinical cancer samples and permeabilized cells (Klepinin *et al.* 2016; Koit *et al.* 2017). Although 2.5 to 5 mM ADP is sufficient to obtain the actual OXPHOS-capacity in many types of permeabilized tissue and cell preparations, experimental validation is required in each specific case.

**2.5.3. Electron transfer*-*state** (**Figure 5C**): O2 flux determined in the ET-state yields an estimate of ET-capacity. The ET-state is defined as the *noncoupled* state with kinetically-saturating concentrations of O2, respiratory substrate, and optimum exogenous uncoupler concentration for maximum O2 flux. Uncouplers are weak lipid-soluble acids, which function as protonophores. These disrupt the barrier function of the mtIM and thus short circuit the protonmotive system, functioning like a clutch in a mechanical system. As a consequence of the nearly collapsed protonmotive force, the driving force is insufficient for phosphorylation, and *J*P» = 0. The most frequently used uncouplers are carbonyl cyanide m-chloro phenyl hydrazone (CCCP), carbonyl cyanide *p*- trifluoromethoxyphenylhydrazone (FCCP), or dinitrophenol (DNP). Stepwise titration of uncouplers stimulates respiration up to or above the level of O2 consumption rates in the OXPHOS-state; respiration is inhibited, however, above optimum uncoupler concentrations (Mitchell 2011). Data obtained with a single dose of uncoupler must be evaluated with caution, particularly when a fixed uncoupler concentration is used in studies exploring a treatment or disease that may alter the mitochondrial content or mitochondrial sensitivity to inhibition by uncouplers. The effect on ET-capacity of the reversed function of F-ATPase (*J*P«; **Figure 5C**) can be evaluated in the presence and absence of extramitochondrial ATP.

**2.5.4. ROX state and *Rox*:** Besides the three fundamental coupling states of mitochondrial

preparations, the state of residual O2 consumption, ROX, which although not a coupling state, is relevant to assess respiratory function (**Figure 1**). . The rate of residual oxygen consumption, *Rox*, is defined as O2 consumption due to oxidative reactions measured after inhibition of ET with rotenone, malonic acid, and antimycin A. Cyanide and azide inhibit not only CIV but catalase and several peroxidases involved in *Rox*. High concentrations of antimycin A, but not rotenone or cyanide, inhibit peroxisomal acyl-CoA oxidase and D-amino acid oxidase (Vamecq *et al.* 1987). *Rox* represents a baseline used to correct respiration measured in defined coupling states. *Rox*-corrected *L*, *P* and *E* not only lower the values of total fluxes, but also change the flux control ratios *L*/*P* and *L*/*E*. *Rox* is not necessarily equivalent to non-

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

mitochondrial reduction of O2, considering O2-consuming reactions in mitochondria that are not related to ET—such as O2 consumption in reactions catalyzed by monoamine oxidases (type A and B), monooxygenases (cytochrome P450 monooxygenases), dioxygenase (sulfur dioxygenase and trimethyllysine dioxygenase), and several hydoxylases. Even isolated mitochondrial fractions, especially those obtained from liver, may be contaminated by peroxisomes. Unfortunately the actual purity is not determined by transmission electron microscopy. This fact makes the exact determination of mitochondrial O2 consumption and mitochondria-associated generation of reactive oxygen species complicated (Schönfeld *et al.* 2009; Speijer 2016; **Figure 2**). The dependence of ROX- linked O2 consumption needs to be studied in detail together with non-ET enzyme activities, availability of specific substrates, O2 concentration, and electron leakage leading to the formation of reactive oxygen species.

**2.5.5. Quantitative relations:** *E* may exceed or be equal to *P*. *E* > *P* is observed in many types of mitochondria, varying between species, tissues, and cell types (Gnaiger 2009). *E*-*P* is the excess ET-

capacity pushing the phosphorylation-flux (**Figure 2C**) to the limit of its capacity for utilizing the protonmotive force. In addition, the magnitude of *E*-*P* depends on the tightness of respiratory coupling

or degree of uncoupling, since an increase of *L* causes *P* to increase towards the limit of *E*. The *excess*

*E-P* capacity, *E*-*P*, therefore, provides a sensitive diagnostic indicator of specific injuries of the phosphorylation-pathway, under conditions when *E* remains constant but *P* declines relative to controls

(**Figure 4**). Substrate cocktails supporting simultaneous convergent electron transfer to the Q-junction for reconstitution of TCA cycle function establish pathway control states with high ET-capacity, and

consequently increase the sensitivity of the *E-P* assay.

*E* cannot theoretically be lower than *P*. *E* < *P* must be discounted as an artefact, which may be caused experimentally by: (*1*) loss of oxidative capacity during the time course of the respirometric

assay, since *E* is measured subsequently to *P*; (*2*) using insufficient uncoupler concentrations; (*3*) using high uncoupler concentrations which inhibit ET (Gnaiger 2008); (*4*) high oligomycin concentrations

applied for measurement of *L* before titrations of uncoupler, when oligomycin exerts an inhibitory effect on *E*. On the other hand, the excess ET-capacity is overestimated if non-saturating [ADP] or [Pi] are used. See State 3 in the next section.

The net OXPHOS-capacity is calculated by subtracting *L* from *P* (**Figure 4**). The net P»/O2 equals P»/(*P-L*), wherein the dissipative LEAK component in the OXPHOS-state may be overestimated. This can be avoided by measuring LEAK-respiration in a state when the protonmotive force is adjusted to its slightly lower value in the OXPHOS-state by titration of an ET inhibitor (Divakaruni and Brand 2011). Any turnover-dependent components of proton leak and slip, however, are underestimated under these conditions (Garlid *et al.* 1993). In general, it is inappropriate to use the terms *ATP production* or *ATP turnover*,for the difference of O2 flux measured in the OXPHOS and LEAK states. *P-L* is the upper limit of OXPHOS-capacity that is freely available for ATP production (corrected for LEAK-respiration) and is fully coupled to phosphorylation with a maximum mechanistic stoichiometry (**Figure 4**).

The rates of LEAK respiration and OXPHOS capacity depend on (*1*) the tightness of coupling under the influence of the respiratory uncoupling mechanisms (**Figure 3**), and (*2*) the coupling stoichiometry, which varies as a function of the substrate type undergoing oxidation in ET-pathways with either two or three coupling sites (**Figure 2B**). When cocktails with NADH-linked substrates and succinate are used, the relative contribution of ET-pathways with three or two coupling sites cannot be controlled experimentally, is difficult to determine, and may shift in transitions between LEAK-, OXPHOS- and ET-states (Gnaiger 2014). Under these experimental conditions, we cannot separate the tightness of coupling *versus* coupling stoichiometry as the mechanisms of respiratory control in the shift of *L*/*P* ratios. The tightness of coupling and fully coupled O2 flux, *P*-*L* (**Table 2**), therefore, are obtained from measurements of coupling control of LEAK respiration, OXPHOS- and ET-capacities in well-defined pathway states, using either pyruvate and malate as substrates or the classical succinate and rotenone substrate-inhibitor combination (**Figure 2B**).

**2.5.6. The steady-state:** Mitochondria represent a thermodynamically open system in non- equilibrium states of biochemical energy transformation. State variables (protonmotive force; redox

states) and metabolic *rates* (fluxes) are measured in defined mitochondrial respiratory *states*. Steady-

states can be obtained only in open systems, in which changes by internal transformations, *e.g.*, O2 consumption, are instantaneously compensated for by external fluxes, *e.g.*, O2 supply, preventing a change of O2 concentration in the system (Gnaiger 1993b). Mitochondrial respiratory states monitored in closed systems satisfy the criteria of pseudo-steady states for limited periods of time, when changes in the system (concentrations of O2, fuel substrates, ADP, Pi, H+) do not exert significant effects on

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

metabolic fluxes (respiration, phosphorylation). Such pseudo-steady states require respiratory media with sufficient buffering capacity and substrates maintained at kinetically-saturating concentrations, and thus depend on the kinetics of the processes under investigation.

*2.6. Classical terminology for isolated mitochondria*

*‘When a code is familiar enough, it ceases appearing like a code; one forgets that there is a*

*decoding mechanism. The message is identical with its meaning’* (Hofstadter 1979).

Chance and Williams (1955; 1956) introduced five classical states of mitochondrial respiration and cytochrome redox states. **Table 3** shows a protocol with isolated mitochondria in a closed respirometric chamber, defining a sequence of respiratory states. States and rates are not specifically distinguished in this nomenclature.

**Table 3. Metabolic states of mitochondria (Chance and**

**Williams, 1956; Table V).**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **State** | **[O2]** | **ADP**  **level** | **Substrate level** | **Respiration rate** | **Rate-limiting substance** |
| 1 | >0 | low | low | slow | ADP |
| 2 | >0 | high | ~0 | slow | substrate |
| 3 | >0 | high | high | fast | respiratory chain |
| 4 | >0 | low | high | slow | ADP |
| 5 | 0 | high | high | 0 | oxygen |

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

**2.6.1. State 1** is obtained after addition of isolated mitochondria to air-saturated isoosmotic/isotonic respiration medium containing Pi, but no fuel substrates and no adenylates, *i.e.*, AMP, ADP, ATP.

**2.6.2. State 2** is induced by addition of a ‘high’ concentration of ADP (typically 100 to 300 µM), which stimulates respiration transiently on the basis of endogenous fuel substrates and phosphorylates

only a small portion of the added ADP. State 2 is then obtained at a low respiratory activity limited by

exhausted endogenous fuel substrate availability (**Table 3**). If addition of specific inhibitors of respiratory complexes such as rotenone does not cause a further decline of O2 flux, State 2 is equivalent to the ROX state (See below.). If inhibition is observed, undefined endogenous fuel substrates are a confounding factor of pathway control, contributing to the effect of subsequently externally added substrates and inhibitors. In contrast to the original protocol, an alternative sequence of titration steps is frequently applied, in which the alternative ‘State 2’ has an entirely different meaning when this second state is induced by addition of fuel substrate without ADP or ATP (LEAK-state; in contrast to State 2 defined in **Table 1** as a ROX state). Some researchers have called this condition as ’pseudostate 4‘ because it has no significant concentrations of adenine nucleotides and hence it is not a near- physiological condition, although it should be used for calculating the net OXPHOS-capacity, *P*-*L*.

**2.6.3. State 3** is the state stimulated by addition of fuel substrates while the ADP concentration is still high (**Table 3**) and supports coupled energy transformation through oxidative phosphorylation.

'High ADP' is a concentration of ADP specifically selected to allow the measurement of State 3 to State

4 transitions of isolated mitochondria in a closed respirometric chamber. Repeated ADP titration re- establishes State 3 at ‘high ADP’. Starting at O2 concentrations near air-saturation (193 or 238 µM O2 at 37 °C or 25 °C and sea level at 1 atm or 101.32 kPa, and an oxygen solubility of respiration medium at 0.92 times that of pure water; Forstner and Gnaiger 1983), the total ADP concentration added must be low enough (typically 100 to 300 µM) to allow phosphorylation to ATP at a coupled O2 flux that does not lead to O2 depletion during the transition to State 4. In contrast, kinetically-saturating ADP concentrations usually are 10-fold higher than 'high ADP', *e.g.,* 2.5 mM in isolated mitochondria. The abbreviation State 3u is occasionally used in bioenergetics, to indicate the state of respiration after titration of an uncoupler, without sufficient emphasis on the fundamental difference between OXPHOS- capacity (*well-coupled* with an endogenous uncoupled component) and ET-capacity (*noncoupled*).

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

**2.6.4. State 4** is a LEAK-state that is obtained only if the mitochondrial preparation is intact and well-coupled. Depletion of ADP by phosphorylation to ATP causes a decline of O2 flux in the transition from State 3 to State 4. Under the conditions of State 4, a maximum protonmotive force and high ATP/ADP ratio are maintained. The gradual decline of *Y*P»/O2 towards diminishing [ADP] at State 4 must be taken into account for calculation of P»/O2 ratios (Gnaiger 2001). State 4 respiration, *L*T (**Table 1**), reflects intrinsic proton leak and ATP hydrolysis activity. O2 flux in State 4 is an overestimation of LEAK-respiration if the contaminating ATP hydrolysis activity recycles some ATP to ADP, *J*P«, which stimulates respiration coupled to phosphorylation, *J*P» > 0. Some degree of mechanical disruption and loss of mitochondrial integrity allows the exposed mitochondrial F-ATPases to hydrolyze the ATP synthesized by the fraction of coupled mitochondria. This can be tested by inhibition of the phosphorylation-pathway using oligomycin, ensuring that *J*P» = 0 (State 4o). On the other hand, the State

4 respiration reached after exhaustion of added ADP is a more physiological condition ,*i.e.*, presence of

ATP, ADP, and even AMP. Sequential ADP titrations re-establish State 3, followed by State 3 to State

4 transitions while sufficient O2 is available. Anoxia may be reached, however, before exhaustion of

ADP (State 5).

**2.6.5. State 5** is the state after exhaustion of O2 in a closed respirometric chamber. Diffusion of

O2 from the surroundings into the aqueous solution may be a confounding factor preventing complete anoxia (Gnaiger 2001). Chance and Williams (1955) provide an alternative definition of State 5, which

gives it the different meaning of ROX versus anoxia: ‘State 5 may be obtained by antimycin A treatment

or by anaerobiosis’.

In **Table 3**, only States 3 and 4 are coupling control states, with the restriction that rates in State

3 may be limited kinetically by non-saturating ADP concentrations.

*2.7. Control and regulation*

The terms metabolic *control* and *regulation* are frequently used synonymously, but are distinguished in metabolic control analysis: ”We could understand the regulation as the mechanism that occurs when a system maintains some variable constant over time, in spite of fluctuations in external conditions (homeostasis of the internal state). On the other hand, metabolic control is the power to change the state of the metabolism in response to an external signal” (Fell 1997). Respiratory control may be induced by experimental control signals that exert an influence on: (*1*) ATP demand and ADP phosphorylation-rate; (*2*) fuel substrate composition, pathway competition; (*3*) available amounts of substrates and O2, *e.g.*, starvation and hypoxia; (*4*) the protonmotive force, redox states, flux–force relationships, coupling, and efficiency; (*5*) Ca2+ and other ions including H+; (*6*) inhibitors, *e.g.*, nitric oxide or intermediary metabolites such as oxaloacetate; (*7*) signalling pathways and regulatory proteins, *e.g.,* insulin resistance, transcription factor hypoxia inducible factor 1.

Mechanisms of respiratory control and regulation include adjustments of: (*1*) enzyme activities by allosteric mechanisms and phosphorylation; (*2*) enzyme content, concentrations of cofactors, and conserved moieties such as adenylates, nicotinamide adenine dinucleotide [NAD+/NADH], coenzyme Q, cytochrome *c*; (*3*) metabolic channeling by supercomplexes; and *(4)* mitochondrial density (enzyme concentrations and membrane area) and morphology (cristae folding, fission and fusion). Mitochondria are targeted directly by hormones, *e.g.*, progesterone and glucacorticoids, which affect their energy metabolism (Lee *et al.* 2013; Gerö and Szabo 2016; Price and Dai 2016; Moreno *et al.* 2017). Evolutionary or acquired differences in the genetic and epigenetic basis of mitochondrial function (or dysfunction) between individuals; age; gender, and hormone concentrations; life style including exercise and nutrition; and environmental issues including thermal, atmospheric, toxic, and pharmacological factors, exert an influence on all control mechanisms listed above. For reviews, see Brown 1992; Gnaiger 1993a, 2009; 2014; Paradies *et al.* 2014; Morrow *et al*. 2017.

Lack of control by a metabolic pathway, *e.g.,* phosphorylation-pathway, means that there will be no response to a variable activating it, *e.g.,* [ADP]. The reverse, however, is not true as the absence

of a response to [ADP] does not exclude the phosphorylation-pathway from having some degree of

control. The degree of control of a component of the OXPHOS-pathway on an output variable, such as O2 flux, will in general be different from the degree of control on other outputs, such as phosphorylation-flux or proton leak flux. Therefore, it is necessary to be specific as to which input and output are under consideration (Fell 1997).

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

Respiratory control refers to the ability of mitochondria to adjust O2 flux in response to external control signals by engaging various mechanisms of control and regulation. Respiratory control is monitored in a mitochondrial preparation under conditions defined as respiratory states, preferentially under near-physiological conditions of temperature, pH, and medium ionic composition, to generate data of higher biological relevance. When phosphorylation of ADP to ATP is stimulated or depressed, an increase or decrease is observed in electron transfer measured as O2 flux in respiratory coupling states of intact mitochondria (‘controlled states’ in the classical terminology of bioenergetics). Alternatively, coupling of electron transfer with phosphorylation is diminished by uncouplers. The corresponding coupling control state is characterized by a high respiratory rate without control by P» (noncoupled or

‘uncontrolled state’).

**3. What is a rate?**

The term *rate* is not adequately defined to be useful for reporting data. Normalization of ‘rates’ leads to a diversity of formats. Application of common and defined units is required for direct transfer of reported results into a database. The second [s] is the SI unit for the base quantity *time*. It is also the standard time-unit used in solution chemical kinetics.

The inconsistency of the meanings of rate becomes apparent when considering Galileo Galilei’s famous principle, that ‘bodies of different weight all fall at the same rate (have a constant acceleration)’ (Coopersmith 2010). A rate may be an extensive quantity, which is a *flow*, *I*, when expressed per object (per number of cells or organisms) or per chamber (per system). ‘System’ is defined as the open or closed chamber of the measuring device. A rate is a *flux*, *J*, when expressed as a size-specific quantity (**Figure 6A; Box 2**).

• **Extendable quantities:** An extendable quantity increases proportionally with system size. For example, mass and volume are extendable quantities. Flow is an extendable quantity. The magnitude of an extendable quantity is completely additive for non-interacting subsystems. The magnitude of these quantities depends on the extent or size of the system (Cohen *et al.*

2008).

• **Size-specific quantities:** ‘The adjective *specific* before the name of an extendable quantity is often used to mean *divided by mass*’ (Cohen *et al.* 2008). In this system-paradigm, mass- specific flux is flow divided by mass of the system (the total mass of everything within the measuring chamber or reactor). Rates are frequently expressed as volume-specific flux. A mass-specific or volume-specific quantity is independent of the extent of non-interacting homogenous subsystems. Tissue-specific quantities (related to the *sample* in contrast to the *system*) are of fundamental interest in the field of comparative mitochondrial physiology, where *specific* refers to the *type of the sample* rather than *mass of the system*. The term *specific*, therefore, must be clarified; *sample*-specific, *e.g.*, muscle mass-specific normalization, is distinguished from *system*-specific quantities (mass or volume; **Figure 6**).

• **Intensive quantities:** In contrast to size-specific properties, forces are intensive quantities defined as the change of an extendable quantity per advancement of an energy transformation (Gnaiger 1993b).

• *NX* and *mX* indicate the number format and mass format, respectively, for expressing the quantity of a sample *X*. When different formats are indicated in symbols of derived quantities, the format (*N*,  *m*) is shown as a subscript (*underlined italic*), as in *I*O2/*NX* and *J*O2/*mX*. Oxygen flow and flux are expressed in the molar format, *n*O2 [mol], but in the volume format, *V*O2 [m3] in ergometry. For mass-specific flux these formats can be distinguished as *Jn*O2/*mX* and *JV*O2/*mX*, respectively. Further examples are given in **Figure 6** and **Table 4**.

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021


1022

1023

1024

**Figure 6. Flow and flux, and normalization in structure- function analysis**

**(A)** When expressing metabolic



‘rate’ measured in a chamber, a

fundamental distinction is made between relating the rate to the experimental sample (left) or chamber (right). The different meanings of rate need to be specified by the chosen normalization. Left: Results are expressed as mass-specific *flux*, *JmX*, per mg protein, dry or wet mass. Cell volume, *V*ce, may be used for normalization (volume-specific flux, *JV*ce). Right: Flow per chamber, *I*, or flux per chamber volume, *JV*, are merely reported for methodological reasons.

**(B)** O2 flow per cell, *I*O2/*N*ce, is the product of mitochondria-specific

flux, mt-density and mass per cell. Unstructured analysis: performance is the product of mass-specific flux, *J*O2/*MX* [mol∙s•1∙kg•1], and *size* (mass per cell). Structured analysis: performance is the product of mitochondrial *function* (mt-specific flux) and *structure* (mt-content). Modified from Gnaiger (2014). For further details see **Table 4**.

**Box 2: Metabolic flows and fluxes: vectoral, vectorial, and scalar**

In a generalization of electrical terms, flow as an extensive quantity (*I*; per system) is distinguished from flux as a size-specific quantity (*J*; per system size). *Flows, I*tr*,* are defined for all transformations as extendable quantities. Electric charge per unit time is electric flow or current, *I*el = d*Q*el∙d*t*-1 [A≡ C∙s-1]. When dividing *I*el by size of the system (cross-sectional area of a ‘wire’), we obtain flux as a size-specific quantity, which is the current density (surface-density of flow) perpendicular to the direction of flux, ***J***el = *I*el∙*A*-1 [A∙m•2] (Cohen et al. 2008). Fluxes with *spatial* geometric direction and magnitude are *vectors*. Vector and scalar *fluxes* are related to flows as ***J***tr = *I*tr∙*A*-1 [mol∙s-1∙m-2] and *J*tr = *I*tr*∙V*-1 [mol∙s•1∙m•3], expressing flux as an area-specific vector or volume-specific vectorial or scalar quantity, respectively (Gnaiger 1993b). We use the metre–kilogram–second–ampere (MKSA) international system of units (SI) for general cases ([m], [kg], [s] and [A]), with decimal SI prefixes for specific applications (**Table 4**).

We suggest defining: (*1*) *vectoral* fluxes, which are translocations as functions of *gradients* with direction in geometric space in continuous systems; (*2*) *vectorial* fluxes, which describe translocations in discontinuous systems and are restricted to information on *compartmental differences* (transmembrane proton flux); and (*3*) *scalar* fluxes, which are transformations in a *homogenous* system (catabolic O2 flux, *J*kO2).

1025

1026

1027

1028

1029

1030

1031

1032

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Expression** | **Symbol** | **Definition** | **Unit** | **Notes** |
| **Sample** | | | | |
| identity of sample | *X* | object: cell, tissue, animal, patient |  |  |
| number of sample entities *X* | *NX* | number of objects | x | 1 |
| mass of sample *X* | *mX* |  | kg | 2 |
| mass of object *X* | *MX* | *MX* = *mX*∙*NX*-1 | kg∙x•1 | 2 |
| **Mitochondria** | | | | |
| mitochondria | mt | *X* = mt |  |  |
| amount of  mt-elementary components | *mtE* | quantity of mt-marker | mtEU |  |
| **Concentrations** | | | | |
| object number concentration | *CNX* | *CNX* = *NX*∙*V*-1 | x∙m•3 | 3 |
| sample mass concentration | *CmX* | *CmX* = *mX*∙*V*-1 | kg∙m•3 |  |
| mitochondrial concentration | *CmtE* | *CmtE* = *mtE*∙*V*-1 | mtEU∙m•3 | 4 |
| specific mitochondrial density | *DmtE* | *DmtE* = *mtE*∙*mX*-1 | mtEU∙kg•1 | 5 |
| mitochondrial content,  *mtE* per object *X* | *mtENX* | -1 | •1 | 6 |
| **O2 flow and flux** |  |  |  | 7 |
| flow, system | *I*O2 | internal flow | mol∙s-1 | 8 |
| volume-specific flux | *JV,*O2 | *JV,*O2 = *I*O2∙*V*-1 | mol∙s-1∙m-3 | 9 |
| flow per object *X* | *I*O2*/NX* | *I*O2*/NX* = *JV,*O2∙*CNX*-1 | mol∙s-1∙x-1 | 10 |
| mass-specific flux | *J*O2/*mX* | -1 | -1 -1 |  |
| mt-marker-specific flux | *J*O2/*mtE* | *J*O2/*mtE* = *JV,*O2∙*CmtE*-1 | mol∙s-1∙mtEU-1 | 11 |

**4. Normalization of rate per sample**

The challenges of measuring mitochondrial respiratory flux are matched by those of normalization. Normalization (**Table 4**) is guided by physicochemical principles, methodological considerations, and conceptual strategies (**Figure 6**).

**Table 4. Sample concentrations and normalization of flux.**

*mtENX* = *mtE*∙*NX*

mtEU∙x

*J*O2/*mX* = *JV,*O2∙*CmX*

mol∙s

∙kg

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1 The unit x for a number is not used by IUPAC. To avoid confusion, the units [kg∙x-1] and [kg] distinguish the mass per object from the mass of a sample that may contain any number of objects. Similarly, the units for flow per system *versus* flow per object are [mol∙s-1] (Note 8) and [mol∙s-1∙x-1] (Note 10).

2 Units are given in the MKSA system (**Box 2**). The *SI* prefix k is used for the *SI* base unit of mass (kg

= 1,000 g). In praxis, various *SI* prefixes are used for convenience, to make numbers easily readable,

*e.g.,* 1 mg tissue, cell or mitochondrial mass instead of 0.000001 kg.

3 In case of cells (sample *X* = cells), the object number concentration is *CN*ce = *N*ce∙*V*-1, and volume may be expressed in [dm3 ≡ L] or [cm3 = mL]. See **Table 5** for different object types.

4 mt-concentration is an experimental variable, dependent on sample concentration: (*1*) *CmtE* = *mtE*∙*V*•1; (*2*) *CmtE* = *mtEX*∙*CNX*; (*3*) *CmtE* = *CmX*∙*DmtE*.

5 If the amount of mitochondria, *mtE*, is expressed as mitochondrial mass, then *DmtE* is the mass fraction of mitochondria in the sample. If *mtE* is expressed as mitochondrial volume, *V*mt, and the

mass of sample, *mX*, is replaced by volume of sample, *VX*, then *DmtE* is the volume fraction of mitochondria in the sample.

-1 -1

1048

6 *mtENX* = *mtE*∙*NX*

= *CmtE*∙*CNX* .

1049

1050

7 O2 can be replaced by other chemicals to study different reactions, *e.g.,* ATP, H2O2, or vesicular compartmental translocations, *e.g.,* Ca2+.

1051

1052

1053

8 *I*O2 and *V* are defined per instrument chamber as a system of constant volume (and constant temperature), which may be closed or open. *I*O2 is abbreviated for *I*rO2, *i.e.*, the metabolic or internal O2 flow of the chemical reaction r in which O2 is consumed, hence the negative stoichiometric

-1

1054

number, *ν*O2 = -1. *I*rO2 = dr*n*O2/d*t*∙*ν*O2

. If r includes all chemical reactions in which O2 participates, then

1055

1056

1057

1058

1059

1060

dr*n*O2 = d*n*O2 – de*n*O2, where d*n*O2 is the change in the amount of O2 in the instrument chamber and de*n*O2

is the amount of O2 added externally to the system. At steady state, by definition d*n*O2 = 0, hence dr*n*O2

= –de*n*O2.

9 *JV,*O2 is an experimental variable, expressed per volume of the instrument chamber.

10 *I*O2*/NX* is a physiological variable, depending on the size of entity *X*.

11 There are many ways to normalize for a mitochondrial marker, that are used in different experimental

-1 -1 -1 •1

1061

approaches: (*1*) *J*O2/*mtE* = *JV,*O2∙*CmtE*

; (*2*) *J*O2/*mtE* = *JV,*O2∙*CmX*

∙*DmtE*

= *J*O2*/mX*∙*DmtE*

; (*3*) *J*O2/*mtE* =

1062

1063

1064

1065

1066

*JV,*O2∙*CNX*•1∙*mtENX*•1 = *I*O2*/NX*∙*mtENX*-1; (*4*) *J*O2/*mtE* = *I*O2∙*mtE*-1. The mt-elementary unit [mtEU] varies depending on the mt-marker.

**Table 5. Sample types, *X*, abbreviations, and quantification.**

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

***a*** Instead of mass, the wet weight or dry weight is frequently stated, *W*w or *W*d. *mX* is mass of the sample [kg], *MX* is mass of the object [kg∙x-1] (**Table 4**).

***b*** Total cell count, *N*ce = *N*vce + *N*dce

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Identity of sample** | *X* | *NX* | **Mass*a*** | **Volume** | **mt-Marker** |
| mitochondrial preparation |  | [x] | [kg] | [m3] | [mtEU] |
| isolated mitochondria | imt |  | *m*mt | *V*mt | *mtE* |
| tissue homogenate | thom |  | *m*thom |  | *mtE*thom |
| permeabilized tissue | pti |  | *m*pti |  | *mtE*pti |
| permeabilized fibre | pfi |  | *m*pfi |  | *mtE*pfi |
| permeabilized cell | pce | *N*pce | *M*pce | *V*pce | *mtE*pce |
| cells*b* | ce | *N*ce | *M*ce | *V*ce | *mtE*ce |
| intact cell, viable cell | vce | *N*vce | *M*vce | *V*vce |  |
| dead cell | dce | *N*dce | *M*dce | *V*dce |  |
| organism | org | *N*org | *M*org | *V*org |  |

*4.1. Flow: per object*

**4.1.1. Number concentration, *CNX*:** Normalization per sample concentration is routinely required to report respiratory data. *CNX* is the experimental number concentration of sample *X*. In the case of animals, *e.g.*, nematodes, *CNX = NX/V* [x∙L-1], where *NX* is the number of organisms in the chamber. Similarly, the number of cells per chamber volume is the number concentration of permeabilized or intact cells *CN*ce *= N*ce*/V* [x∙L•1], where *N*ce is the number of cells in the chamber (**Table 4**).

**4.1.2. Flow per object, *I*O2/*NX*:** O2 flow per cell is calculated from volume-specific O2 flux, *JV,*O2 [nmol∙s•1∙L•1] (per *V* of the measurement chamber [L]), divided by the number concentration of cells. The total cell count is the sum of viable and dead cells, *N*ce = *N*vce+*N*dce (**Table 5**). The cell viability index, *VI* = *N*vce/*N*ce, is the ratio of viable cells (*N*vce; before experimental permeabilization) per total cell

count. After experimental permeabilization, all cells are permeabilized, *N*pce = *N*ce. The cell viability index can be used to normalize respiration for the number of cells that have been viable before experimental permeabilization, *I*O2/*N*vce = *I*O2/*N*ce/*VI*, considering that mitochondrial respiratory dysfunction in dead cells should be eliminated as a confounding factor.

The complexity changes when the object is a whole organism studied as an experimental model.

The scaling law in respiratory physiology reveals a strong interaction between O2 flow and individual body mass: *basal* metabolic rate (flow) does not increase linearly with body mass, whereas *maximum*

mass-specific O2 flux, 𝑉̇O2max or 𝑉̇O2peak, is approximately constant across a large range of individual

body mass (Weibel and Hoppeler 2005). Individuals, breeds, and species, however, deviate substantially

from this relationship. 𝑉̇O2peak of human endurance athletes is 60 to 80 mL O2·min•1·kg•1 body mass,

converted to *J*O2peak/*M*org of 45 to 60 nmol·s-1·g-1 (Gnaiger 2014; **Table 6**).

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

*4.2. Size-specific flux: per sample size*

**4.2.1. Sample concentration, *CmX*:** Considering permeabilized tissue, homogenate or cells as the sample, *X*, the sample mass is *mX* [mg], which is frequently measured as wet or dry weight, *W*w or *W*d [mg], respectively, or as amount of protein, *m*Protein. The sample concentration is the mass of the subsample per volume of the measurement chamber, *CmX* = *mX*/*V* [g∙L-1 = mg∙mL•1]. *X* is the type of sample—isolated mitochondria, tissue homogenate, permeabilized fibres or cells (**Table 5**).

**4.2.2. Size-specific flux:** Cellular O2 flow can be compared between cells of identical size. To take into account changes and differences in cell size, normalization is required to obtain cell size- specific or mitochondrial marker-specific O2 flux (Renner *et al.* 2003).

• **Mass-specific flux, *J*O2/*mX*** [mol∙s-1∙kg-1]: Mass-specific flux is obtained by expressing respiration per mass of sample, *mX* [mg]. Flow per cell is divided by mass per cell, *J*O2*/m*ce = *I*O2/*N*ce/*MN*ce. Or chamber volume-specific flux, *JV*,O2, is divided by mass concentration of *X* in the chamber, *J*O2*/mX* = *JV*,O2/*CmX*.

• **Cell volume-specific flux**, ***J*O2/*VX*** [mol∙s-1∙m-3]: Sample volume-specific flux is obtained by expressing respiration per volume of sample. For example, in the case of using cells as sample will be the volume of cells added to the chamber (**Figure 6**).

If size-specific O2 flux is constant and independent of sample size, then there is no interaction between the subsystems. For example, a 1.5 mg and a 3.0 mg muscle sample respire at identical mass-

specific flux. Mass-specific O2 flux, however, may change with the mass of a tissue sample, cells or isolated mitochondria in the measuring chamber, in which the nature of the interaction becomes an issue. Therefore, cell density must be optimized, particularly in experiments carried out in wells, considering the confluency of the cell monolayer or clumps of cells (Salabei *et al.* 2014).

*4.3. Marker-specific flux: per mitochondrial content*

Tissues can contain multiple cell populations that may have distinct mitochondrial subtypes. Mitochondria undergo dynamic fission and fusion cycles, and can exist in multiple stages and sizes that may be altered by a range of factors. The isolation of mitochondria (often achieved through differential centrifugation) can therefore yield a subsample of the mitochondrial types present in a tissue, depending on the isolation protocols utilized ,*e.g.,* centrifugation speed. This possible bias should be taken into account when planning experiments using isolated mitochondria. Different sizes of mitochondria are enriched at specific centrifugation speeds, which can be used strategically for isolation of mitochondrial subpopulations.

Part of the mitochondrial content of a tissue is lost during preparation of isolated mitochondria. The fraction of isolated mitochondria obtained from a tissue sample is expressed as mitochondrial recovery. At a high mitochondrial recovery, the fraction of isolated mitochondria is more representative of the total mitochondrial population than in preparations characterized by low recovery. Determination of the mitochondrial recovery and yield is based on measurement of the concentration of a mitochondrial marker in the stock of isolated mitochondria, *CmtE*,stock, and crude tissue homogenate, *CmtE*,thom, which simultaneously provides information on the specific mitochondrial density in the sample, *DmtE* (**Table**

**4**).

When discussing concepts of normalization, it is essential to consider the question posed by the study. If the study aims at comparing tissue performance—such as the effects of a treatment on a specific

tissue, then normalization for tissue mass or protein content is appropriate. However, if the aim is to

find differences in mitochondrial function independent of mitochondrial density (**Table 4**), then normalization to a mitochondrial marker is imperative (**Figure 6**). One cannot assume that quantitative

changes in various markers—such as mitochondrial proteins—necessarily occur in parallel with one

another. It should be established that the marker chosen is not selectively altered by the performed treatment. In conclusion, the normalization must reflect the question under investigation to reach a satisfying answer. On the other hand, the goal of comparing results across projects and institutions requires standardization on normalization for entry into a databank.

**4.3.1. Mitochondrial concentration, *CmtE*, and mitochondrial markers:** Mitochondrial organelles compose a dynamic cellular reticulum in various states of fusion and fission. Hence, the

definition of an ’amount‘ of mitochondria is often misconceived: mitochondria cannot be counted reliably as a number of occurring elementary components. Therefore, quantification of the "amount" of

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

mitochondria depends on the measurement of chosen mitochondrial markers. ”Mitochondria are the structural and functional elementary units of cell respiration” (Gnaiger 2014). The quantity of a mitochondrial marker can reflect the amount of *mitochondrial elementary components*, *mtE*, expressed in various mitochondrial elementary units [mtEU] specific for each measured mt-marker (**Table 4**). However, since mitochondrial quality may change in response to stimuli—particularly in mitochondrial dysfunction (Campos *et al.* 2017) and after exercise training (Pesta *et al.* 2011) and during aging (Daum *et al.* 2013)—some markers can vary while others are unchanged: (*1*) Mitochondrial volume and membrane area are structural markers, whereas mitochondrial protein mass is commonly used as a marker for isolated mitochondria. (*2*) Molecular and enzymatic mitochondrial markers (amounts or activities) can be selected as matrix markers, *e.g.*, citrate synthase activity, mtDNA; mtIM-markers, *e.g.*, cytochrome *c* oxidase activity, *aa*3 content, cardiolipin, or mtOM-markers, *e.g.*, the voltage-dependent anion channel (VDAC), TOM20. (*3*) Extending the measurement of mitochondrial marker enzyme activity to mitochondrial pathway capacity, ET- or OXPHOS-capacity can be considered as an integrative functional mitochondrial marker.

Depending on the type of mitochondrial marker, the mitochondrial elementary component, *mtE*, is expressed in marker-specific units. Mitochondrial concentration in the measurement chamber and the tissue of origin are quantified as (*1*) a quantity for normalization in functional analyses, *CmtE*, and (*2*) a physiological output that is the result of mitochondrial biogenesis and degradation, *DmtE*, respectively (**Table 4**). It is recommended, therefore, to distinguish *experimental mitochondrial concentration*, *CmtE*

Not in Table 4

= *mtE*/*V* and *physiological mitochondrial density*, *DmtE* = *mtE*/*mX*. Then mitochondrial density is the amount of mitochondrial elementary components per mass of tissue, which is a biological variable (**Figure 6**). The experimental variable is mitochondrial density multiplied by sample mass concentration in the measuring chamber, *CmtE* = *DmtE*∙*CmX*, or mitochondrial content multiplied by sample number concentration, *CmtE* = *mtEX*∙*CNX* (**Table 4**).

**4.3.2. mt-Marker-specific flux, *J*O2/*mtE***: Volume-specific metabolic O2 flux depends on: (*1*) the sample concentration in the volume of the instrument chamber, *CmX*, or *CNX*; (*2*) the mitochondrial density in the sample, *DmtE* = *mtE*/*mX* or *mtEX* = *mtE*/*NX*; and (*3*) the specific mitochondrial activity or performance per elementary mitochondrial unit, *J*O2/*mtE* = *JV*,O2/*CmtE* [mol∙s-1∙mtEU-1] (**Table 4**). Obviously, the numerical results for *J*O2/*mtE* vary with the type of mitochondrial marker chosen for measurement of *mtE* and *CmtE* = *mtE*/*V* [mtEU∙m-3].

Different methods are involved in the quantification of mitochondrial markers and have different strengths. Some problems are common for all mitochondrial markers, *mtE*: (*1*) Accuracy of

measurement is crucial, since even a highly accurate and reproducible measurement of O2 flux results in an inaccurate and noisy expression if normalized by a biased and noisy measurement of a

mitochondrial marker. This problem is acute in mitochondrial respiration because the denominators used (the mitochondrial markers) are often small moieties of which accurate and precise determination is difficult. This problem can be avoided when O2 fluxes measured in substrate-uncoupler-inhibitor titration protocols are normalized for flux in a defined respiratory reference state, which is used as an *internal* marker and yields flux control ratios, *FCR*s. *FCR*s are independent of externally measured markers and, therefore, are statistically robust, considering the limitations of ratios in general (Jasienski and Bazzaz 1999). *FCR*s indicate qualitative changes of mitochondrial respiratory control, with highest quantitative resolution, separating the effect of mitochondrial density or concentration on *J*O2/*mX* and *I*O2/*NX* from that of function per elementary mitochondrial marker, *J*O2/*mtE* (Pesta *et al.* 2011; Gnaiger

2014). (*2*) If mitochondrial quality does not change and only the amount of mitochondria varies as a

determinant of mass-specific flux, any marker is equally qualified in principle; then in practice selection of the optimum marker depends only on the accuracy and precision of measurement of the mitochondrial marker. (*3*) If mitochondrial flux control ratios change, then there may not be any best mitochondrial marker. In general, measurement of multiple mitochondrial markers enables a comparison and evaluation of normalization for these mitochondrial markers. Particularly during postnatal development, the activity of marker enzymes—such as cytochrome *c* oxidase and citrate synthase— follows different time courses (Drahota *et al.* 2004). Evaluation of mitochondrial markers in healthy controls is insufficient for providing guidelines for application in the diagnosis of pathological states and specific treatments.

In line with the concept of the respiratory control ratio (Chance and Williams 1955a), the most readily used normalization is that of flux control ratios and flux control factors (Gnaiger 2014). Selection

of the state of maximum flux in a protocol as the reference state has the advantages of: (*1*) internal

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

normalization; (*2*) statistically validated linearization of the response in the range of 0 to 1; and (*3*) consideration of maximum flux for integrating a large number of elementary steps in the OXPHOS- or ET-pathways. This reduces the risk of selecting a functional marker that is specifically altered by the treatment or pathology, yet increases the chance that the highly integrative pathway is disproportionately affected, *e.g.,* the OXPHOS- rather than ET-pathway in case of an enzymatic defect in the phosphorylation-pathway. In this case, additional information can be obtained by reporting flux control ratios based on a reference state that indicates stable tissue-mass specific flux.

Stereological determination of mitochondrial content via two-dimensional transmission electron microscopy can have limitations due to the dynamics of mitochondrial size (Meinild Lundby *et al.*

2017). Accurate determination of three-dimensional volume by two-dimensional microscopy can be both time consuming and statistically challenging (Larsen *et al.* 2012).

The validity of using mitochondrial marker enzymes (citrate synthase activity, CI to CIV amount

or activity) for normalization of flux is limited in part by the same factors that apply to flux control ratios. Strong correlations between various mitochondrial markers and citrate synthase activity (Reichmann *et al.* 1985; Boushel *et al.* 2007; Mogensen *et al.* 2007) are expected in a specific tissue of healthy persons and in disease states not specifically targeting citrate synthase. Citrate synthase activity is acutely modifiable by exercise (Tonkonogi *et al.* 1997; Leek *et al.* 2001). Evaluation of mitochondrial markers related to a selected age and sex cohort cannot be extrapolated to provide recommendations for normalization in respirometric diagnosis of disease, in different states of development and ageing, different cell types, tissues, and species. mtDNA normalized to nDNA via qPCR is correlated to functional mitochondrial markers including OXPHOS- and ET-capacity in some cases (Puntschart *et al.*

1995; Wang *et al.* 1999; Menshikova *et al.* 2006; Boushel *et al.* 2007; Ehinger *et al.* 2015), but lack of such correlations have been reported (Menshikova *et al.* 2005; Schultz and Wiesner 2000; Pesta *et al.*

2011). Several studies indicate a strong correlation between cardiolipin content and increase in

mitochondrial function with exercise (Menshikova *et al.* 2005; Menshikova *et al.* 2007; Larsen *et al.*

2012; Faber *et al.* 2014), but it has not been evaluated as a general mitochondrial biomarker in disease. With no single best mitochondrial marker, a good strategy is to quantify several different biomarkers to

minimize the decorrelating effects caused by diseases, treatments, or other factors. Determination of multiple markers, particularly a matrix marker and a marker from the mtIM, allows tracking changes in

mitochondrial quality defined by their ratio.

**5. Normalization of rate per system**

*5.1. Flow: per chamber*

The experimental system (experimental chamber) is part of the measurement instrument, separated from the environment as an isolated, closed, open, isothermal or non-isothermal system (**Table 4**). Reporting O2 flows per respiratory chamber, *I*O2 [nmol∙s-1], restricts the analysis to intra- experimental comparison of relative differences.

*5.2. Flux: per chamber volume*

**5.2.1. System-specific flux, *JV*,O2**: We distinguish between (*1*) the *system* with volume *V* and mass *m* defined by the system boundaries, and (*2*) the *sample* or *objects* with volume *VX* and mass *mX* that are enclosed in the experimental chamber (**Figure 6**). Metabolic O2 flow per object, *I*O2/*NX*, is the total O2 flow in the system divided by the number of objects, *NX*, in the system. *I*O2/*NX* increases as the mass of the object is increased. Sample mass-specific O2 flux, *J*O2/*mX* should be independent of the mass of the sample studied in the instrument chamber, but system volume-specific O2 flux, *JV*,O2 (per volume of the instrument chamber), increases in proportion to the mass of the sample in the chamber. Although *JV*,O2 depends on mass-concentration of the sample in the chamber, it should be independent of the chamber (system) volume at constant sample mass. There are practical limitations to increasing the mass- concentration of the sample in the chamber, when one is concerned about crowding effects and instrumental time resolution.

**5.2.2. Advancement per volume:** When the reactor volume does not change during the reaction, which is typical for liquid phase reactions, the volume-specific *flux of a chemical reaction* r is the time

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

derivative of the advancement of the reaction per unit volume, *JV*,rB = dr*ξ*B/d*t*∙*V*-1 [(mol∙s•1)∙L•1]. The *rate of concentration change* is d*c*B/d*t* [(mol∙L•1)∙s•1], where concentration is *c*B = *n*B/*V*. There is a difference between (*1*) *JV*,rO2 [mol∙s•1∙L•1] and (*2*) rate of concentration change [mol∙L•1∙s•1]. These merge into a single expression only in closed systems. In open systems, internal transformations (catabolic flux, O2 consumption) are distinguished from external flux (such as O2 supply). External fluxes of all substances are zero in closed systems. In a closed chamber, O2 consumption (internal flux of catabolic reactions k), *I*kO2 [pmol∙s-1] causes a decline in the amount of O2 in the system, *n*O2 [nmol]. Normalization of these quantities for the volume of the system, *V* [L ≡ dm3], yields volume-specific O2 flux, *JV*,kO2 = *I*kO2/*V* [nmol∙s-1∙L-1], and O2 concentration, [O2] or *c*O2 = *n*O2/*V* [µmol∙L•1 = µM = nmol∙mL•1]. Instrumental background O2 flux is due to external flux into a non-ideal closed respirometer, so total volume- specific flux has to be corrected for instrumental background O2 flux—O2 diffusion into or out of the instrumental chamber. *JV*,kO2 is relevant mainly for methodological reasons and should be compared with the accuracy of instrumental resolution of background-corrected flux, *e.g.*, ±1 nmol∙s•1∙L-1 (Gnaiger

2001). ‘Metabolic’ or catabolic indicates O2 flux, *J*kO2, corrected for: (*1*) instrumental background O2 flux; (*2*) chemical background O2 flux due to autoxidation of chemical components added to the incubation medium; and (*3*) *Rox* for O2-consuming side reactions unrelated to the catabolic pathway k.

**6. Conversion of units**

Many different units have been used to report the O2 consumption rate, OCR (**Table 6**). SI base units provide the common reference to introduce the theoretical principles (**Figure 6**), and are used with appropriately chosen *SI* prefixes to express numerical data in the most practical format, with an effort towards unification within specific areas of application (**Table 7**). Reporting data in *SI* units—including the mole [mol], coulomb [C], joule [J], and second [s]—should be encouraged, particularly by journals that propose the use of *SI* units.

**Table 6. Conversion of various formats and units used in respirometry and ergometry.** e- is the number of electrons or reducing equivalents. *z*B is the charge number of entity B.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Format | 1 Unit ∙ | Multiplication factor | *SI*-unit | Notes |
| *n* | ng.atom O∙s-1 (2 e-) | 0.5 | nmol O2∙s•1 |  |
| *n* | ng.atom O∙min-1 (2 e-) | 8.33 | pmol O2∙s•1 |  |
| *n* | natom O∙min-1 (2 e-) | 8.33 | pmol O2∙s•1 |  |
| *n* | nmol O2∙min-1 (4 e-) | 16.67 | pmol O2∙s•1 |  |
| *n* | nmol O2∙h-1 (4 e-) | 0.2778 | pmol O2∙s•1 |  |
| *V* to *n* | mL O2∙min-1 at STPD*a* | 0.744 | µmol O2∙s•1 | 1 |
| *e* to *n* | W = J/s at -470 kJ/mol O2 | -2.128 | µmol O2∙s•1 |  |
| *e* to *n* | mA = mC∙s-1 (*z*H+ = 1) | 10.36 | nmol H+∙s•1 | 2 |
| *e* to *n* | mA = mC∙s-1 (*z*O2 = 4) | 2.59 | nmol O2∙s•1 | 2 |
| *n* to *e* | nmol H+∙s•1 (*z*H+ = 1) | 0.09649 | mA | 3 |
| *n* to *e* | nmol O2∙s•1 (*z*O2 = 4) | 0.38594 | mA | 3 |

1293

1294

1295

1296

1297

1298

1299

1300

1 At standard temperature and pressure dry (STPD: 0 °C = 273.15 K and 1 atm = 101.325 kPa =

760 mmHg), the molar volume of an ideal gas, *V*m, and *V*m,O2 is 22.414 and 22.392 L∙mol-1, respectively. Rounded to three decimal places, both values yield the conversion factor of 0.744.

For comparison at normal temperature and pressure dry (NTPD: 20 °C), *V*m,O2 is 24.038 L∙mol-1. Note that the *SI* standard pressure is 100 kPa.

2 The multiplication factor is 106/(*z*B∙*F*).

3 The multiplication factor is *z*B∙*F*/106.

1301

**Table 7. Conversion of units with preservation of numerical values.**

|  |  |  |  |
| --- | --- | --- | --- |
| Name | Frequently used unit | Equivalent unit | Notes |
| volume-specific flux, *JV,*O2 | pmol∙s-1∙mL-1 | nmol∙s-1∙L-1 | 1 |
|  | mmol∙s-1∙L-1 | mol∙s-1∙m-3 |  |
| cell-specific flow, *I*O2/cell | pmol∙s-1∙10-6 cells | amol∙s-1∙cell-1 | 2 |
|  | pmol∙s-1∙10-9 cells | zmol∙s-1∙cell-1 | 3 |
| cell number concentration, *CN*ce | 106 cells∙mL-1 | 109 cells∙L-1 |  |
| mitochondrial protein concentration, *CmtE* | 0.1 mg∙mL-1 | 0.1 g∙L-1 |  |
| mass-specific flux, *J*O2*/m* | pmol∙s-1∙mg-1 | nmol∙s-1∙g-1 | 4 |
| catabolic power, *P*k | µW∙10-6 cells | pW∙cell-1 | 1 |
| volume | 1,000 L | m3 (1,000 kg) |  |
|  | L | dm3 (kg) |  |
|  | mL | cm3 (g) |  |
|  | µL | mm3 (mg) |  |
|  | fL | µm3 (pg) | 5 |
| amount of substance concentration | M = mol∙L-1 | mol∙dm-3 |  |

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1 pmol: picomole = 10-12 mol 4 nmol: nanomole = 10-9 mol

2 amol: attomole = 10-18 mol 5 fL: femtolitre = 10-15 L

3 zmol: zeptomole = 10-21 mol

Although volume is expressed as m3 using the *SI* base unit, the litre [dm3] is a conventional unit of volume for concentration and is used for most solution chemical kinetics. If one multiplies *I*O2/*N*ce by *CN*ce, then the result will not only be the amount of O2 [mol] consumed per time [s-1] in one litre [L•1], but also the change in O2 concentration per second (for any volume of an ideally closed system). This is ideal for kinetic modeling as it blends with chemical rate equations where concentrations are typically expressed in mol∙L-1 (Wagner *et al.* 2011). In studies of multinuclear cells—such as differentiated skeletal muscle cells—it is easy to determine the number of nuclei but not the total number of cells. A generalized concept, therefore, is obtained by substituting cells by nuclei as the sample entity. This does not hold, however, for non-nucleated platelets.

For studies of cells, we recommend that respiration be expressed, as far as possible, as: (*1*) O2

flux normalized for a mitochondrial marker, for separation of the effects of mitochondrial quality and

content on cell respiration (this includes *FCR*s as a normalization for a functional mitochondrial marker); (*2*) O2 flux in units of cell volume or mass, for comparison of respiration of cells with different cell size (Renner *et al.* 2003) and with studies on tissue preparations, and (*3*) O2 flow in units of attomole (10-18 mol) of O2 consumed per second by each cell [amol∙s•1∙cell-1], numerically equivalent to [pmol∙s•1∙10•6 cells]. This convention allows information to be easily used when designing experiments in which O2 flow must be considered. For example, to estimate the volume-specific O2 flux in an instrument chamber that would be expected at a particular cell number concentration, one simply needs to multiply the flow per cell by the number of cells per volume of interest. This provides the amount of O2 [mol] consumed per time [s-1] per unit volume [L-1]. At an O2 flow of 100 amol∙s•1∙cell-1 and a cell density of 109 cells∙L•1 (106 cells∙mL•1), the volume-specific O2 flux is 100 nmol∙s-1∙L-1 (100 pmol∙s•1∙mL•1).

ET-capacity in human cell types including HEK 293, primary HUVEC, and fibroblasts ranges from 50 to 180 amol∙s-1∙cell-1, measured in intact cells in the noncoupled state (see Gnaiger 2014). At

100 amol∙s-1∙cell-1 corrected for *Rox*, the current across the mt-membranes, *I*H+***e***, approximates 193

pA∙cell-1 or 0.2 nA per cell. See Rich (2003) for an extension of quantitative bioenergetics from the molecular to the human scale, with a transmembrane proton flux equivalent to 520 A in an adult at a catabolic power of •110 W. Modelling approaches illustrate the link between protonmotive force and

currents (Willis *et al.* 2016).

We consider isolated mitochondria as powerhouses and proton pumps as molecular machines to

relate experimental results to energy metabolism of the intact cell. The cellular P»/O2 based on oxidation

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348

1349

1350

1351

1352

1353

1354

1355

1356

1357

1358

1359

1360

1361

1362

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

1373

1374

1375

1376

1377

1378

1379

1380

1381

1382

1383

1384

1385

1386

1387

1388

1389

1390

1391

1392

of glycogen is increased by the glycolytic (fermentative) substrate-level phosphorylation of 3 P»/Glyc or 0.5 mol P» for each mol O2 consumed in the complete oxidation of a mol glycosyl unit (Glyc). Adding

0.5 to the mitochondrial P»/O2 ratio of 5.4 yields a bioenergetic cell physiological P»/O2 ratio close to

6. Two NADH equivalents are formed during glycolysis and transported from the cytosol into the mitochondrial matrix, either by the malate-aspartate shuttle or by the glycerophosphate shuttle (**Figure**

**2A**) resulting in different theoretical yields of ATP generated by mitochondria, the energetic cost of which potentially must be taken into account. Considering also substrate-level phosphorylation in the

TCA cycle, this high P»/O2 ratio not only reflects proton translocation and OXPHOS studied in isolation, but integrates mitochondrial physiology with energy transformation in the living cell (Gnaiger 1993a).

**7. Conclusions**

Catabolic cell respiration is the process of exergonic and exothermic energy transformation in which scalar redox reactions are coupled to vectorial ion translocation across a semipermeable membrane, which separates the small volume of a bacterial cell or mitochondrion from the larger volume of its surroundings. The electrochemical exergy can be partially conserved in the phosphorylation of ADP to ATP or in ion pumping, or dissipated in an electrochemical short-circuit. Respiration is thus clearly distinguished from fermentation as the counterpart of cellular core energy metabolism. An O2 flux balance scheme illustrates the relationships and general definitions (**Figures 1 and 2**).

**Box 3: Recommendations for studies with mitochondrial preparations**

● Normalization of respiratory rates should be provided as far as possible:

1. *Biophysical normalization*: on a per cell basis as O2 flow; this may not be possible when dealing with coenocytic organisms or tissues without cross-walls separating individual cells (*e.g.*, filamentous fungi, muscle fibers)

2. *Cellular normalization*: per g protein; per cell- or tissue-mass as mass-specific O2 flux;

Muscle fibers do not fit the definition of coenocytic

per cell volume as cell volume-specific flux

3. *Mitochondrial normalization*: per mitochondrial marker as mt-specific flux.

With information on cell size and the use of multiple normalizations, maximum potential information is available (Renner *et al.* 2003; Wagner *et al.* 2011; Gnaiger 2014). Reporting flow in a respiratory chamber [nmol∙s-1] is discouraged, since it restricts the analysis to intra-experimental comparison of relative (qualitative) differences.

● Catabolic mitochondrial respiration is distinguished from residual O2 consumption. Fluxes in mitochondrial coupling states should be, as far as possible, corrected for residual O2 consumption.

● Different mechanisms of uncoupling should be distinguished by defined terms. The tightness of

coupling relates to these uncoupling mechanisms, whereas the coupling stoichiometry varies as a function the substrate type involved in ET-pathways with either three or two redox proton pumps

operating in series. Separation of tightness of coupling from the pathway-dependent coupling stoichiometry is possible only when the substrate type undergoing oxidation remains the same for

respiration in LEAK-, OXPHOS-, and ET-states. In studies of the tightness of coupling, therefore, simple substrate•inhibitor combinations should be applied to exlcude a shift in substrate competition that may occur when providing physiological substrate cocktails.

● In studies of isolated mitochondria, the mitochondrial recovery and yield should be reported.

Experimental criteria such as transmission electron microscopy for evaluation of purity versus integrity should be considered. Mitochondrial markers—such as citrate synthase activity as an enzymatic matrix marker—provide a link to the

tissue of origin on the basis of calculating the mitochondrial recovery, *i.e.*, the fraction of

mitochondrial marker obtained from a unit mass of tissue. Total mitochondrial protein is frequently applied as a mitochondrial marker, which is restricted to isolated mitochondria.

● In studies of permeabilized cells, the viability of the cell culture or cell suspension of origin should

be reported. Normalization should be evaluated for total cell count or viable cell count.

● Terms and symbols are summarized in **Table 8**. Their use will facilitate transdisciplinary communication and support further development of a consistent theory of bioenergetics and

mitochondrial physiology. Technical terms related to and defined with normal words can be used as index terms in databases, support the creation of ontologies towards semantic information processing

1393

1394

1395

1396

1397

1398

1399

1400

1401

1402

1403

1404

1405

1406

1407

1408

1409

1410

1411

1412

1413

1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432

1433

1434

1435

1436

1437

1438

1439

1440

1441

1442

1443

1444

1445

1446

1447

(MitoPedia), and help in communicating analytical findings as impactful data-driven stories.

‘*Making data available without making it understandable may be worse than not making it available at all*’ (National Academies of Sciences, Engineering, and Medicine 2018). Success will depend on

taking further steps: (*1*) exhaustive text-mining considering Omics data and functional data; (*2*) network

analysis of Omics data with bioinformatics tools; (*3*) cross-validation with distinct bioinformatics approaches; (*4*) correlation with functional data; (*5*) guidelines for biological validation of network

data. This is a call to carefully contribute to FAIR principles (Findable, Accessible, Interoperable,

Reusable) for the sharing of scientific data.

**Table 8. Terms, symbols, and units.**

**Term Symbol Unit Links and comments**

alternative quinol oxidase AOX Figure 2B

amount of substance B *n*B [mol]

ATP yield per O2 *Y*P»/O2 P»/O2 ratio measured in any respiratory state

catabolic reaction k Figure 1 and 3 catabolic respiration *J*kO2 *varies* Figure 1 and 3

cell number *N*ce [x] *N*ce = *N*vce + *N*dce; Table 5 cell respiration *J*rO2 *varies* Figure 1

cell viability index *VI VI* = *N*vce/*N*ce = 1- *N*dce/*N*ce

charge number of entity B *z*B Table 6; *z*O2 = 4

Complexes I to IV CI to CIV respiratory ET Complexes; Figure

2B concentration of substance B *c*B = *n*B∙*V*•1; [B] [mol∙m•3] Box 2 coupling control state CCS Section 2.4.1

dead cell number *N*dce [x] non-viable cells, loss of plasma membrane barrier function; Table 5

electric format *e* [C] Table 6

electron transfer system ETS state; Figure 2B, Figure 4

flow, for substance B *I*B [mol∙s•1] system-related extensive quantity; Figure 6

flux, for substance B *J*B *varies* size-specific quantitiy; Figure 6 inorganic phosphate Pi Figure 2C

inorganic phosphate carrier PiC Figure 2C

intact cell number,

viable cell number *N*vce [x] viable cells, intact of plasma membrane barrier function; Table 5

LEAK state LEAK state; Table 1, Figure 4 mass format *m* [kg] Table 4, Figure 6

mass of sample *X mX* [kg] Table 4

mass, dry mass *m*d [kg] mass of sample *X*; Figure 6 (frequently called dry weight)

mass, wet mass *m*w [kg] mass of sample *X*; Figure 6 (frequently called wet weight)

mass of object *X MX* = *mX*∙*NX*-1 [kg∙x-1] mass of entity *X*; Table 4

MITOCARTA [https://www.broadinstitute.org/scientific- community/science/programs/metab](https://www.broadinstitute.org/scientific-community/science/programs/metabolic-disease-program/publications/mitocarta/mitocarta-in-0)

[olic-disease- program/publications/mitocarta/mito carta-in-0](https://www.broadinstitute.org/scientific-community/science/programs/metabolic-disease-program/publications/mitocarta/mitocarta-in-0)

1448

1449

1450

1451

MitoPedia <http://www.bioblast.at/index.php/MitoPedia> mitochondria or mitochondrial mt Box 1

mitochondrial DNA mtDNA Box 1 mitochondrial concentration *CmtE* = *mtE*∙*V*-1 [mtEU∙m•3] Table 4

-1

1452

1453

mitochondrial content *mtEX* [mtEU∙x•1] *mtEX* = *mtE*∙*NX*

mitochondrial

; Table 4

1454

1455

1456

1457

1458

1459

1460

1461

1462

1463

1464

1465

1466

1467

1468

1469

1470

1471

1472

1473

1474

1475

1476

1477

1478

1479

1480

1481

1482

1483

1484

1485

1486

1487

1488

1489

1490

1491

1492

1493

1494

1495

1496

1497

1498

1499

1500

1501

1502

1503

elementary component *mtE* [mtEU] quantity of mt-marker; Table 4 mitochondrial elementary unit mtEU *varies* specific units for mt-marker; Table 4 mitochondrial inner membrane mtIM MIM is widely used; the first M is

replaced by mt; Figure 2; Box 1 mitochondrial outer membrane mtOM MOM is widely used; the first M is

replaced by mt; Figure 2; Box 1

mitochondrial recovery *YmtE* fraction of *mtE* recovered in sample from the tissue of origin

mitochondrial yield *YmtE*/*m* mt-yield per tissues mass; *YmtE*/*m* =

*YmtE* ∙ *DmtE*

molar format *n* [mol] Table 6

negative neg Figure 4 number concentration of *X CNX* [x∙m-3] Table 4

number format  *N* [x] Table 4, Figure 6 number of entities *X NX* [x] Table 4, Figure 6 number of entity B *N*B [x] Table 4

oxidative phosphorylation OXPHOS state; Table 1, Figure 4 oxygen concentration *c*O2 = *n*O2∙*V*•1 [mol∙m•3] [O2]; Section 3.2 oxygen flux, in reaction r *J*rO2 *varies* Figure 1

pathway control state PCS Section 2.2

permeabilized cell number *N*pce [x] experimental permeabilization of plasma membrane; Table 5

phosphorylation of ADP to ATP P» Section 2.2

P»/O2 ratio P»/O2 mechanistic *Y*P»/O2, calculated from pump stoichiometries; Figure 2B

positive pos Figure 4 proton in the negative compartment H+neg Figure 4 proton in the positive compartment H+pos Figure 4

rate of electron transfer in ET state *E* ET-capacity; Table 1 rate of LEAK respiration *L* Table 1

rate of oxidative phosphorylation *P* OXPHOS capacity; Table 1 rate of residual oxygen consumption *Rox* Table 1, Figure 1

residual oxygen consumption ROX state; Table 1

respiratory supercomplex SC I*n*III*n*IV*n* supramolecular assemblies composed of variable copy numbers (*n*) of CI, CIII and CIV; Box 1

specific mitochondrial density *DmtE* = *mtE*∙*mX*-1 [mtEU∙kg•1] Table 4 substrate-uncoupler-inhibitor-

titration protocol SUIT ## volume *V* [m-3] Table 7 volume format *V* [m-3] Table 6

Experimentally, respiration is separated in mitochondrial preparations from the interactions with the fermentative pathways of the intact cell. OXPHOS analysis is based on the study of mitochondrial preparations complementary to bioenergetic investigations of intact cells and organisms—from model organisms to the human species including healthy and diseased persons (patients). Different mechanisms of respiratory uncoupling have to be distinguished (**Figure 3**). Metabolic fluxes measured in defined coupling and pathway control states (**Figures 5 and 6**) provide insights into the meaning of cellular and organismic respiration.

1504

1505

1506

1507

1508

1509

1510

1511

1512

1513

1514

1515

1516

1517

1518

1519

1520

1521

1522

1523

1524

1525

1526

1527

1528

1529

1530

1531

1532

1533

1534

1535

1536

1537

1538

1539

1540

1541

1542

1543

1544

1545

1546

1547

1548

1549

1550

1551

1552

1553

1554

1555

1556

1557

1558

1559

1560

1561

1562

The optimal choice for expressing mitochondrial and cell respiration as O2 flow per biological sample, and normalization for specific tissue-markers (volume, mass, protein) and mitochondrial markers (volume, protein, content, mtDNA, activity of marker enzymes, respiratory reference state) is guided by the scientific question under study. Interpretation of the data depends critically on appropriate normalization (**Figure 6**).

MitoEAGLE can serve as a gateway to better diagnose mitochondrial respiratory adaptations and defects linked to genetic variation, age-related health risks, sex-specific mitochondrial performance, lifestyle with its effects on degenerative diseases, and thermal and chemical environment. The present recommendations on coupling control states and rates, linked to the concept of the protonmotive force, are focused on studies using mitochondrial preparations (**Box 3**). These will be extended in a series of reports on pathway control of mitochondrial respiration, respiratory states in intact cells, and harmonization of experimental procedures.

**Acknowledgements**

We thank M. Beno for management assistance. This publication is based upon work from COST Action CA15203 MitoEAGLE, supported by COST (European Cooperation in Science and Technology), and K-Regio project MitoFit (E.G.).

**Competing financial interests:** E.G. is founder and CEO of Oroboros Instruments, Innsbruck, Austria.

**References**

Altmann R (1894) Die Elementarorganismen und ihre Beziehungen zu den Zellen. Zweite vermehrte Auflage.

Verlag Von Veit & Comp, Leipzig:160 pp.

Baggeto LG, Testa-Perussini R (1990) Role of acetoin on the regulation of intermediate metabolism of Ehrlich ascites tumor mitochondria: its contribution to membrane cholesterol enrichment modifying passive proton permeability. Arch Biochem Biophys 283:341-8.

Beard DA (2005) A biophysical model of the mitochondrial respiratory system and oxidative phosphorylation.

PLoS Comput Biol 1(4):e36.

Benda C (1898) Weitere Mitteilungen über die Mitochondria. Verh Dtsch Physiol Ges:376-83. Birkedal R, Laasmaa M, Vendelin M (2014) The location of energetic compartments affects energetic

communication in cardiomyocytes. Front Physiol 5:376.

Blier PU, Dufresne F, Burton RS (2001) Natural selection and the evolution of mtDNA-encoded peptides:

evidence for intergenomic co-adaptation. Trends Genet 17:400-6.

Blier PU, Guderley HE (1993) Mitochondrial activity in rainbow trout red muscle: the effect of temperature on the ADP-dependence of ATP synthesis. J Exp Biol 176:145-58.

Breton S, Beaupré HD, Stewart DT, Hoeh WR, Blier PU (2007) The unusual system of doubly uniparental inheritance of mtDNA: isn't one enough? Trends Genet 23:465-74.

Brown GC (1992) Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J

284:1-13.

Burger G, Gray MW, Forget L, Lang BF (2013) Strikingly bacteria-like and gene-rich mitochondrial genomes throughout jakobid protists. Genome Biol Evol 5:418-38.

Calvo SE, Klauser CR, Mootha VK (2016) MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Research 44:D1251-7.

Calvo SE, Julien O, Clauser KR, Shen H, Kamer KJ, Wells JA, Mootha VK (2017) Comparative analysis of mitochondrial N-termini from mouse, human, and yeast. Mol Cell Proteomics 16:512-23.

Campos JC, Queliconi BB, Bozi LHM, Bechara LRG, Dourado PMM, Andres AM, Jannig PR, Gomes KMS, Zambelli VO, Rocha-Resende C, Guatimosim S, Brum PC, Mochly-Rosen D, Gottlieb RA, Kowaltowski AJ,

Ferreira JCB (2017) Exercise reestablishes autophagic flux and mitochondrial quality control in heart failure. Autophagy 13:1304-317.

Canton M, Luvisetto S, Schmehl I, Azzone GF (1995) The nature of mitochondrial respiration and discrimination between membrane and pump properties. Biochem J 310:477-81.

Carrico C, Meyer JG, He W, Gibson BW, Verdin E (2018) The mitochondrial acylome emerges: proteomics, regulation by Sirtuins, and metabolic and disease implications. Cell Metab 27:497-512.

Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and development. Cell 125:1241-52. Chance B, Williams GR (1955a) Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen

utilization. J Biol Chem 217:383-93.

Chance B, Williams GR (1955b) Respiratory enzymes in oxidative phosphorylation: III. The steady state. J Biol

Chem 217:409-27.

1563

1564

1565

1566

1567

1568

1569

1570

1571

1572

1573

1574

1575

1576

1577

1578

1579

1580

1581

1582

1583

1584

1585

1586

1587

1588

1589

1590

1591

1592

1593

1594

1595

1596

1597

1598

1599

1600

1601

1602

1603

1604

1605

1606

1607

1608

1609

1610

1611

1612

1613

1614

1615

1616

1617

1618

1619

1620

1621

1622

1623

1624

Chance B, Williams GR (1955c) Respiratory enzymes in oxidative phosphorylation. IV. The respiratory chain. J Biol Chem 217:429-38.

Chance B, Williams GR (1956) The respiratory chain and oxidative phosphorylation. Adv Enzymol Relat Subj

Biochem 17:65-134.

Chowdhury SK, Djordjevic J, Albensi B, Fernyhough P (2015) Simultaneous evaluation of substrate -dependent oxygen consumption rates and mitochondrial membrane potential by TMRM and safranin in cortical mitochondria. Biosci Rep 36:e00286.

Cobb LJ, Lee C, Xiao J, Yen K, Wong RG, Nakamura HK, Mehta HH, Gao Q, Ashur C, Huffman DM, Wan J, Muzumdar R, Barzilai N, Cohen P (2016) Naturally occurring mitochondrial-derived peptides are age- dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY) 8:796-

809.

Cohen ER, Cvitas T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor HL (2008) Quantities, units and smbols in physical chemistry, IUPAC Green Book, 3rd Edition, 2nd Printing, IUPAC & RSC Publishing, Cambridge.

Cooper H, Hedges LV, Valentine JC, eds (2009) The handbook of research synthesis and meta-analysis. Russell

Sage Foundation.

Coopersmith J (2010) Energy, the subtle concept. The discovery of Feynman’s blocks from Leibnitz to Einstein.

Oxford University Press:400 pp.

Cummins J (1998) Mitochondrial DNA in mammalian reproduction. Rev Reprod 3:172-82.

Dai Q, Shah AA, Garde RV, Yonish BA, Zhang L, Medvitz NA, Miller SE, Hansen EL, Dunn CN, Price TM (2013) A truncated progesterone receptor (PR-M) localizes to the mitochondrion and controls cellular respiration. Mol Endocrinol 27:741-53.

Daum B, Walter A, Horst A, Osiewacz HD, Kühlbrandt W (2013) Age-dependent dissociation of ATP synthase dimers and loss of inner-membrane cristae in mitochondria. Proc Natl Acad Sci U S A 110:15301-6.

Divakaruni AS, Brand MD (2011) The regulation and physiology of mitochondrial proton leak. Physiology

(Bethesda) 26:192-205.

Doerrier C, Garcia-Souza LF, Krumschnabel G, Wohlfarter Y, Mészáros AT, Gnaiger E (2018) High-Resolution FluoRespirometry and OXPHOS protocols for human cells, permeabilized fibres from small biopsies of muscle, and isolated mitochondria. Methods Mol Biol 1782 (Palmeira CM, Moreno AJ, eds): Mitochondrial Bioenergetics, 978-1-4939-7830-4.

Doskey CM, van ‘t Erve TJ, Wagner BA, Buettner GR (2015) Moles of a substance per cell is a highly

informative dosing metric in cell culture. PLOS ONE 10:e0132572.

Drahota Z, Milerová M, Stieglerová A, Houstek J, Ostádal B (2004) Developmental changes of cytochrome *c*

oxidase and citrate synthase in rat heart homogenate. Physiol Res 53:119-22.

Duarte FV, Palmeira CM, Rolo AP (2014) The role of microRNAs in mitochondria: small players acting wide.

Genes (Basel) 5:865-86.

Ehinger JK, Morota S, Hansson MJ, Paul G, Elmér E (2015) Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients. J Neurol 262:1493-503.

Ernster L, Schatz G (1981) Mitochondria: a historical review. J Cell Biol 91:227s-55s.

Estabrook RW (1967) Mitochondrial respiratory control and the polarographic measurement of ADP:O ratios.

Methods Enzymol 10:41-7.

Faber C, Zhu ZJ, Castellino S, Wagner DS, Brown RH, Peterson RA, Gates L, Barton J, Bickett M, Hagerty L, Kimbrough C, Sola M, Bailey D, Jordan H, Elangbam CS (2014) Cardiolipin profiles as a potential biomarker of mitochondrial health in diet-induced obese mice subjected to exercise, diet-restriction and ephedrine treatment. J Appl Toxicol 34:1122-9.

Feagin JE, Harrell MI, Lee JC, Coe KJ, Sands BH, Cannone JJ, Tami G, Schnare MN, Gutell RR (2012) The fragmented mitochondrial ribosomal RNAs of *Plasmodium falciparum*. PLoS One 7:e38320.

Fell D (1997) Understanding the control of metabolism. Portland Press.

Forstner H, Gnaiger E (1983) Calculation of equilibrium oxygen concentration. In: Polarographic Oxygen Sensors. Aquatic and Physiological Applications. Gnaiger E, Forstner H (eds), Springer, Berlin, Heidelberg, New York:321-33.

Garlid KD, Beavis AD, Ratkje SK (1989) On the nature of ion leaks in energy-transducing membranes. Biochim

Biophys Acta 976:109-20.

Garlid KD, Semrad C, Zinchenko V. Does redox slip contribute significantly to mitochondrial respiration? In: Schuster S, Rigoulet M, Ouhabi R, Mazat J-P, eds (1993) Modern trends in biothermokinetics. Plenum Press, New York, London:287-93.

Gerö D, Szabo C (2016) Glucocorticoids suppress mitochondrial oxidant production via upregulation of uncoupling protein 2 in hyperglycemic endothelial cells. PLoS One 11:e0154813.

Gnaiger E. Efficiency and power strategies under hypoxia. Is low efficiency at high glycolytic ATP production a paradox? In: Surviving Hypoxia: Mechanisms of Control and Adaptation. Hochachka PW, Lutz PL, Sick T,

Rosenthal M, Van den Thillart G, eds (1993a) CRC Press, Boca Raton, Ann Arbor, London, Tokyo:77-109. Gnaiger E (1993b) Nonequilibrium thermodynamics of energy transformations. Pure Appl Chem 65:1983-2002.

1625

1626

1627

1628

1629

1630

1631

1632

1633

1634

1635

1636

1637

1638

1639

1640

1641

1642

1643

1644

1645

1646

1647

1648

1649

1650

1651

1652

1653

1654

1655

1656

1657

1658

1659

1660

1661

1662

1663

1664

1665

1666

1667

1668

1669

1670

1671

1672

1673

1674

1675

1676

1677

1678

1679

1680

1681

1682

1683

1684

Gnaiger E (2001) Bioenergetics at low oxygen: dependence of respiration and phosphorylation on oxygen and adenosine diphosphate supply. Respir Physiol 128:277-97.

Gnaiger E (2009) Capacity of oxidative phosphorylation in human skeletal muscle. New perspectives of mitochondrial physiology. Int J Biochem Cell Biol 41:1837-45.

Gnaiger E (2014) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 4th ed.

Mitochondr Physiol Network 19.12. Oroboros MiPNet Publications, Innsbruck:80 pp.

Gnaiger E, Méndez G, Hand SC (2000) High phosphorylation efficiency and depression of uncoupled respiration in mitochondria under hypoxia. Proc Natl Acad Sci USA 97:11080-5.

Greggio C, Jha P, Kulkarni SS, Lagarrigue S, Broskey NT, Boutant M, Wang X, Conde Alonso S, Ofori E, Auwerx J, Cantó C, Amati F (2017) Enhanced respiratory chain supercomplex formation in response to exercise in human skeletal muscle. Cell Metab 25:301-11.

Hinkle PC (2005) P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1706:1-11. Hofstadter DR (1979) Gödel, Escher, Bach: An eternal golden braid. A metaphorical fugue on minds and

machines in the spirit of Lewis Carroll. Harvester Press:499 pp.

Illaste A, Laasmaa M, Peterson P, Vendelin M (2012) Analysis of molecular movement reveals latticelike obstructions to diffusion in heart muscle cells. Biophys J 102:739-48.

Jasienski M, Bazzaz FA (1999) The fallacy of ratios and the testability of models in biology. Oikos 84:321-26. Jepihhina N, Beraud N, Sepp M, Birkedal R, Vendelin M (2011) Permeabilized rat cardiomyocyte response

demonstrates intracellular origin of diffusion obstacles. Biophys J 101:2112-21.

Karnkowska A, Vacek V, Zubáčová Z, Treitli SC, Petrželková R, Eme L, Novák L, Žárský V, Barlow LD, Herman EK, Soukal P, Hroudová M, Doležal P, Stairs CW, Roger AJ, Eliáš M, Dacks JB, Vlček Č, Hampl V (2016) A eukaryote without a mitochondrial organelle. Curr Biol 26:1274-84.

Klepinin A, Ounpuu L, Guzun R, Chekulayev V, Timohhina N, Tepp K, Shevchuk I, Schlattner U, Kaambre T (2016) Simple oxygraphic analysis for the presence of adenylate kinase 1 and 2 in normal and tumor cells. J

Bioenerg Biomembr 48:531-48.

Klingenberg M (2017) UCP1 - A sophisticated energy valve. Biochimie 134:19-27.

Koit A, Shevchuk I, Ounpuu L, Klepinin A, Chekulayev V, Timohhina N, Tepp K, Puurand M,Truu L, Heck K, Valvere V, Guzun R, Kaambre T (2017) Mitochondrial respiration in human colorectal and breast cancer clinical material is regulated differently. Oxid Med Cell Longev 1372640.

Komlódi T, Tretter L (2017) Methylene blue stimulates substrate-level phosphorylation catalysed by succinyl- CoA ligase in the citric acid cycle. Neuropharmacology 123:287-98.

Korn E (1969) Cell membranes: structure and synthesis. Annu Rev Biochem 38:263–88.

Lai N, M Kummitha C, Rosca MG, Fujioka H, Tandler B, Hoppel CL (2018) Isolation of mitochondrial subpopulations from skeletal muscle: optimizing recovery and preserving integrity. Acta Physiol (Oxf):e13182. doi: 10.1111/apha.13182.

Lane N (2005) Power, sex, suicide: mitochondria and the meaning of life. Oxford University Press:354 pp. Larsen S, Nielsen J, Neigaard Nielsen C, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel RC, Helge

JW, Dela F, Hey-Mogensen M (2012) Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol 590:3349-60.

Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P (2015) The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces

obesity and insulin resistance. Cell Metab 21:443-54.

Lee SR, Kim HK, Song IS, Youm J, Dizon LA, Jeong SH, Ko TH, Heo HJ, Ko KS, Rhee BD, Kim N, Han J (2013) Glucocorticoids and their receptors: insights into specific roles in mitochondria. Prog Biophys Mol Biol 112:44-54.

Leek BT, Mudaliar SR, Henry R, Mathieu-Costello O, Richardson RS (2001) Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle. Am J Physiol Regul Integr Comp Physiol

280:R441-7.

Lemieux H, Blier PU, Gnaiger E (2017) Remodeling pathway control of mitochondrial respiratory capacity by temperature in mouse heart: electron flow through the Q-junction in permeabilized fibers. Sci Rep 7:2840.

Lenaz G, Tioli G, Falasca AI, Genova ML (2017) Respiratory supercomplexes in mitochondria. In: Mechanisms of primary energy trasduction in biology. M Wikstrom (ed) Royal Society of Chemistry Publishing, London, UK:296-337.

Liu S, Roellig DM, Guo Y, Li N, Frace MA, Tang K, Zhang L, Feng Y, Xiao L (2016) Evolution of mitosome metabolism and invasion-related proteins in *Cryptosporidium*. BMC Genomics 17:1006.

Margulis L (1970) Origin of eukaryotic cells. New Haven: Yale University Press.

Meinild Lundby AK, Jacobs RA, Gehrig S, de Leur J, Hauser M, Bonne TC, Flück D, Dandanell S, Kir k N, Kaech A, Ziegler U, Larsen S, Lundby C (2018) Exercise training increases skeletal muscle mitochondrial volume density by enlargement of existing mitochondria and not de novo biogenesis. Acta Physiol 222, e12905.

1685

1686

1687

1688

1689

1690

1691

1692

1693

1694

1695

1696

1697

1698

1699

1700

1701

1702

1703

1704

1705

1706

1707

1708

1709

1710

1711

1712

1713

1714

1715

1716

1717

1718

1719

1720

1721

1722

1723

1724

1725

1726

1727

1728

1729

1730

1731

1732

1733

1734

1735

1736

1737

1738

1739

1740

1741

1742

1743

1744

1745

Menshikova EV, Ritov VB, Fairfull L, Ferrell RE, Kelley DE, Goodpaster BH (2006) Effects of exercise on mitochondrial content and function in aging human skeletal muscle. J Gerontol A Biol Sci Med Sci 61:534-

40.

Menshikova EV, Ritov VB, Ferrell RE, Azuma K, Goodpaster BH, Kelley DE (2007) Characteristics of skeletal muscle mitochondrial biogenesis induced by moderate-intensity exercise and weight loss in obesity. J Appl Physiol (1985) 103:21-7.

Menshikova EV, Ritov VB, Toledo FG, Ferrell RE, Goodpaster BH, Kelley DE (2005) Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity. Am J Physiol Endocrinol Metab

288:E818-25.

Miller GA (1991) The science of words. Scientific American Library New York:276 pp.

Mitchell P (1961) Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 191:144-8.

Mitchell P (2011) Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biochim Biophys

Acta Bioenergetics 1807:1507-38.

Mogensen M, Sahlin K, Fernström M, Glintborg D, Vind BF, Beck-Nielsen H, Højlund K (2007) Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 56:1592-9.

Mohr PJ, Phillips WD (2015) Dimensionless units in the SI. Metrologia 52:40-7.

Moreno M, Giacco A, Di Munno C, Goglia F (2017) Direct and rapid effects of 3,5-diiodo-L-thyronine (T2).

Mol Cell Endocrinol 7207:30092-8.

Morrow RM, Picard M, Derbeneva O, Leipzig J, McManus MJ, Gouspillou G, Barbat-Artigas S, Dos Santos C, Hepple RT, Murdock DG, Wallace DC (2017) Mitochondrial energy deficiency leads to hyperproliferation of skeletal muscle mitochondria and enhanced insulin sensitivity. Proc Natl Acad Sci U S A 114:2705-10.

Murley A, Nunnari J (2016) The emerging network of mitochondria-organelle contacts. Mol Cell 61:648-53. National Academies of Sciences, Engineering, and Medicine (2018) International coordination for science data

infrastructure: Proceedings of a workshop—in brief. Washington, DC: The National Academies Press. doi:

https://doi.org/10.17226/25015.

Oemer G, Lackner L, Muigg K, Krumschnabel G, Watschinger K, Sailer S, Lindner H, Gnaiger E, Wortmann SB, Werner ER, Zschocke J, Keller MA (2018) The molecular structural diversity of mitochondrial cardiolipins. Proc Nat Acad Sci U S A 115:4158-63.

Palmfeldt J, Bross P (2017) Proteomics of human mitochondria. Mitochondrion 33:2-14.

Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G (2014) Functional role of cardiolipin in mitochondrial bioenergetics. Biochim Biophys Acta 1837:408-17.

Pesta D, Gnaiger E (2012) High-Resolution Respirometry. OXPHOS protocols for human cells and permeabilized fibres from small biopsies of human muscle. Methods Mol Biol 810:25-58.

Pesta D, Hoppel F, Macek C, Messner H, Faulhaber M, Kobel C, Parson W, Burtscher M, Schocke M, Gnaiger

E (2011) Similar qualitative and quantitative changes of mitochondrial respiration following strength and endurance training in normoxia and hypoxia in sedentary humans. Am J Physiol Regul Integr Comp Physiol

301:R1078–87.

Price TM, Dai Q (2015) The role of a mitochondrial progesterone receptor (PR-M) in progesterone action.

Semin Reprod Med 33:185-94.

Puchowicz MA, Varnes ME, Cohen BH, Friedman NR, Kerr DS, Hoppel CL (2004) Oxidative phosphorylation analysis: assessing the integrated functional activity of human skeletal muscle mitochondria – case studies. Mitochondrion 4:377-85. Puntschart A, Claassen H, Jostarndt K, Hoppeler H, Billeter R (1995) mRNAs of enzymes involved in energy metabolism and mtDNA are increased in endurance-trained athletes. Am J Physiol 269:C619-25.

Quiros PM, Mottis A, Auwerx J (2016) Mitonuclear communication in homeostasis and stress. Nat Rev Mol

Cell Biol 17:213-26.

Rackham O, Mercer TR, Filipovska A (2012) The human mitochondrial transcriptome and the RNA-binding proteins that regulate its expression. WIREs RNA 3:675–95.

Reichmann H, Hoppeler H, Mathieu-Costello O, von Bergen F, Pette D (1985) Biochemical and ultrastructural

changes of skeletal muscle mitochondria after chronic electrical stimulation in rabbits. Pflugers Arch 404:1-

9.

Renner K, Amberger A, Konwalinka G, Gnaiger E (2003) Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells. Biochim Biophys Acta 1642:115-23.

Rice DW, Alverson AJ, Richardson AO, Young GJ, Sanchez-Puerta MV, Munzinger J, Barry K, Boore JL, Zhang Y, dePamphilis CW, Knox EB, Palmer JD (2016) Horizontal transfer of entire genomes via mitochondrial fusion in the angiosperm *Amborella*. Science 342:1468-73.

Rich P (2003) Chemiosmotic coupling: The cost of living. Nature 421:583. Rich PR (2013) Chemiosmotic theory. Encyclopedia Biol Chem 1:467-72.

Roger JA, Munoz-Gomes SA, Kamikawa R (2017) The origin and diversification of mitochondria. Curr Biol

27:R1177-92.

1746

1747

1748

1749

1750

1751

1752

1753

1754

1755

1756

1757

1758

1759

1760

1761

1762

1763

1764

1765

1766

1767

1768

1769

1770

1771

1772

1773

1774

1775

1776

1777

1778

1779

1780

1781

1782

1783

1784

1785

1786

1787

1788

1789

1790

1791

1792

1793

1794

1795

1796

1797

1798

1799

1800

1801

1802

1803

1804

Rostovtseva TK, Sheldon KL, Hassanzadeh E, Monge C, Saks V, Bezrukov SM, Sackett DL (2008) Tubulin binding blocks mitochondrial voltage-dependent anion channel and regulates respiration. Proc Natl Acad Sci USA 105:18746-51.

Rustin P, Parfait B, Chretien D, Bourgeron T, Djouadi F, Bastin J, Rötig A, Munnich A (1996) Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells. J Biol Chem

271:14785-90.

Saks VA, Veksler VI, Kuznetsov AV, Kay L, Sikk P, Tiivel T, Tranqui L, Olivares J, Winkler K, Wiedemann F, Kunz WS (1998) Permeabilised cell and skinned fiber techniques in studies of mitochondrial function in

vivo. Mol Cell Biochem 184:81-100.

Salabei JK, Gibb AA, Hill BG (2014) Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat Protoc 9:421-38.

Sazanov LA (2015) A giant molecular proton pump: structure and mechanism of respiratory complex I. Nat Rev

Mol Cell Biol 16:375-88.

Schneider TD (2006) Claude Shannon: biologist. The founder of information theory used biology to formulate the channel capacity. IEEE Eng Med Biol Mag 25:30-3.

Schönfeld P, Dymkowska D, Wojtczak L (2009) Acyl-CoA-induced generation of reactive oxygen species in mitochondrial preparations is due to the presence of peroxisomes. Free Radic Biol Med 47:503-9.

Schultz J, Wiesner RJ (2000) Proliferation of mitochondria in chronically stimulated rabbit skeletal muscle--

transcription of mitochondrial genes and copy number of mitochondrial DNA. J Bioenerg Biomembr 32:627-

34.

Speijer D (2016) Being right on Q: shaping eukaryotic evolution. Biochem J 473:4103-27.

Sugiura A, Mattie S, Prudent J, McBride HM (2017) Newly born peroxisomes are a hybrid of mitochondrial and

ER-derived pre-peroxisomes. Nature 542:251-4.

Simson P, Jepihhina N, Laasmaa M, Peterson P, Birkedal R, Vendelin M (2016) Restricted ADP movement in cardiomyocytes: Cytosolic diffusion obstacles are complemented with a small number of open mitochondrial voltage-dependent anion channels. J Mol Cell Cardiol 97:197-203.

Stucki JW, Ineichen EA (1974) Energy dissipation by calcium recycling and the efficiency of calcium transport in rat-liver mitochondria. Eur J Biochem 48:365-75.

Tonkonogi M, Harris B, Sahlin K (1997) Increased activity of citrate synthase in human skeletal muscle after a single bout of prolonged exercise. Acta Physiol Scand 161:435-6.

Torralba D, Baixauli F, Sánchez-Madrid F (2016) Mitochondria know no boundaries: mechanisms and functions of intercellular mitochondrial transfer. Front Cell Dev Biol 4:107. eCollection 2016.

Vamecq J, Schepers L, Parmentier G, Mannaerts GP (1987) Inhibition of peroxisomal fatty acyl -CoA oxidase by antimycin A. Biochem J 248:603-7.

Waczulikova I, Habodaszova D, Cagalinec M, Ferko M, Ulicna O, Mateasik A, Sikurova L, Ziegelhöffer A (2007) Mitochondrial membrane fluidity, potential, and calcium transients in the myocardium from acute

diabetic rats. Can J Physiol Pharmacol 85:372-81.

Wagner BA, Venkataraman S, Buettner GR (2011) The rate of oxygen utilization by cells. Free Radic Biol Med

51:700-712.

Wang H, Hiatt WR, Barstow TJ, Brass EP (1999) Relationships between muscle mitochondrial DNA content, mitochondrial enzyme activity and oxidative capacity in man: alterations with disease. Eur J Appl Physiol Occup Physiol 80:22-7.

Watt IN, Montgomery MG, Runswick MJ, Leslie AG, Walker JE (2010) Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondria. Proc Natl Acad Sci U S A 107:16823-7.

Weibel ER, Hoppeler H (2005) Exercise-induced maximal metabolic rate scales with muscle aerobic capacity. J Exp Biol 208:1635–44.

White DJ, Wolff JN, Pierson M, Gemmell NJ (2008) Revealing the hidden complexities of mtDNA inheritance.

Mol Ecol 17:4925–42.

Wikström M, Hummer G (2012) Stoichiometry of proton translocation by respiratory complex I and its mechanistic implications. Proc Natl Acad Sci U S A 109:4431-6.

Williams EG, Wu Y, Jha P, Dubuis S, Blattmann P, Argmann CA, Houten SM, Amariuta T, Wolski W, Zamboni N, Aebersold R, Auwerx J (2016) Systems proteomics of liver mitochondria function. Science 352 (6291):aad0189

Willis WT, Jackman MR, Messer JI, Kuzmiak-Glancy S, Glancy B (2016) A simple hydraulic analog model of oxidative phosphorylation. Med Sci Sports Exerc 48:990-1000.

Zíková A, Hampl V, Paris Z, Týč J, Lukeš J (2016) Aerobic mitochondria of parasitic protists: diverse genomes and complex functions. Mol Biochem Parasitol 209:46-57.

1805

1806

1807

1808

1809

1810

1811

1812

1813

1814

1815

1816

1817

1818

1819

1820

1821

1822

1823

1824

1825

1826

1827

1828

1829

1830

1831

1832

1833

1834

1835

1836

1837

1838

1839

1840

1841

1842

1843

1844

1845

1846

1847

1848

1849

1850

1851

1852

1853

1854

1855

1856

1857

1858

1859

1860

**Supplement**

**S1. Manuscript phases and versions - an open-access apporach**

This manuscript on ‘Mitochondrial respiratory states and rates’ is a position statement in the frame of COST Action

CA15203 MitoEAGLE. The list of co-authors evolved beyond phase 1 in the bottom-up spirit of COST.

The global MitoEAGLE network made it possible to collaborate with a large number of co-authors to reach consensus on the present manuscript. Nevertheless, we do not consider scientific progress to be supported by

‘declaration’ statements (other than on ethical or political issues). Our manuscript aims at providing arguments for further debate rather than pushing opinions. We hope to initiate a much broader process of discussion and want to raise the awareness of the importance of a consistent terminology for reporting of scientific data in the field of bioenergetics, mitochondrial physiology and pathology. Quality of research requires quality of communication.

Some established researchers in the field may not want to re-consider the use of jargon which has become

established despite deficiencies of accuracy and meaning. In the long run, superior standards will become accepted. We hope to contribute to this evolutionary process, with an emphasis on harmonization rather than standardization. *Phase 1* The protonmotive force and respiratory control

<http://www.mitoeagle.org/index.php/The_protonmotive_force_and_respiratory_control>

• 2017-04-09 to 2017-09-18 (44 versions)

• 2017-09-21 to 2018-02-06 (21 versions)

<http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2017-09-21>

2017-11-11: Print version (16) for MiP2017/MitoEAGLE conference in Hradec Kralove

*Phase 2* Mitochondrial respiratory states and rates: Building blocks of mitochondrial physiology Part 1 <http://www.mitoeagle.org/index.php/MitoEAGLE_preprint_2018-02-08>

• 2018-02-08 – (42 Versions up to 2018-09-24) *Phase 3* Submission to a preprint server: [BioRxiv](http://www.mitoeagle.org/index.php/BioRxiv) *Phase 4* Journal submission

CELL METABOLISM, aiming at indexing by *The Web of Science* and *PubMed*. We expect feedback from many colleagues until the end of May, to prepare a final circular to all co-authors in June 2018.

**S2. Authors**

This manuscript developed as an open invitation to scientists and students to join as co-authors, to provide a balanced view of mitochondrial respiratory control and a consensus statement on reporting data of mitochondrial respiration in terms of metabolic flows and fluxes.

Co-authors are added in alphabetical order based upon a first draft written by the corresponding author, who edited all versions. *Co-authors confirm that they have read the final manuscript, possibly have made additions or suggestions for improvement, and agree to implement the recommendations into future manuscripts, presentations and teaching materials.*

We continue to invite comments and suggestions, particularly if you are an early career investigator adding an open future-oriented perspective, or an established scientist providing a balanced historical basis. Your critical input into the quality of the manuscript will be most welcome, improving our aims to be educational, general, consensus-oriented, and in practice be helpful to students working in mitochondrial respiratory physiology.

To join as a co-author, please feel free to focus on a particular section, providing direct input and references, and contributing to the scope of the manuscript from the perspective of your expertise. Your comments will be largely posted on the discussion page of the MitoEAGLE preprint website.

If you prefer to submit comments in the format of a referee's evaluation rather than a contribution as a co- author, we will be glad to distribute your views to the updated list of co-authors for a balanced response. We would

ask for your consent on this open bottom-up policy.

**S3. Joining COST Actions**

• CA15203 MitoEAGLE - <http://www.cost.eu/COST_Actions/ca/CA15203>

• CA16225 EU-CARDIOPROTECTION - <http://www.cost.eu/COST_Actions/ca/CA16225>

• CA17129 CardioRNA - <http://www.cost.eu/COST_Actions/ca/CA17129>

Mitochondrial respiratory

*).* states and rates:

*MITO* Building blocks of mitochondrial physiology

Part 1- [www.](http://www/)mitoeagle.org/index.php/MitoEAGLE\_preprint\_2018-02-08

*Gnaiger E1·2, corresponding author 1Medical University Innsbruck*

*355 co-authors, MitoEAGLE Working Group 2Qroboros, Innsbruck, Austria*

Clarity of concept and consistency of nomenclature facilitate effective transdisciplinary communication, education, and ultimately further discovery.

Adhering to uniform

standards and harmonizing the terminology concerning mitochondrial respiratory states and rates will support the development of databases of mitochondriaI

Recommendations on coupling control states and rates are focused on studies with mitochondrial preparations. Fig.1: Respiration is defined by 0 2 flux balance.

Fig.2: OXPHOS analysis is based on the study of mt- preparations.

Metabolic fluxes measured in defined coupling and pathway control states provide insights into the meaning of cellular respiration. Fig.3: Interpretation of respiratory rates depends critically on appropriate normalization.

Figure 1. From mitochondrialto externalrespiration

MitochOndrial (mt) resp1rat1on is the oxidat1on of fuel substrates (electron donors) and reduction of 02 catalysed by the

electron transfer system, ETS:

0

mt-catabolic resp ration, exclud1ng

o,

*co,*

0

External

respiration

o mt-res1dual oxygen consumpt1on, *Rox.*

(b) Total cellular 02 consumption, Including

*mt'Rox,* El non-mt catabolic *Rox,*

particularl y by perox1somal ox1dases, and

o non-mt *Rox* unrelated to catabolism.

@ External

respiration, including

o aerobic microbial

respiration, and

e extracellular 02

consumption.

Figure 2. Respiratory states (ET,OXPHOS,LEAK)

and corresponding rates *(E, P,* L)

Net OXPHOS·capaclty,*P-L,* and excess capacity,*E· P.* B

Table 1. Coupling states and residual oxygen consumptoi nin mitochondrial

preparationsIn relation to respiration- and phosphorylation-flux, .A.o,and Jp.,

and protonmotive force, *ap.* Couplng states are estabtished at kinetJcally­

*N,.*

r.,..· J

.

flu•,J-




Figure 3. Normalization of rate A: Cell respiratoi n Is normalized for (1) the experimental Sample (flow per object, mass-specific flux, or cell-volume-specific flux); or (2) for methodological reasons for

the Chamber volume.

B: Flow per cell [amol 02• s·1·cel·l 1] is flux per chamber volume, *Jv* [nmol 0 2 ·s·'-L·1],

---

saluralmg concenltatoons of fuelsubslrales and 0,.

Number

t

divided by cell concentration

In the chamber, *NcJV* [cells·L· '], which is Number analysis. In Structure

leak-<k'lletl<k"ll

r spirdlion

and cation cycling AIJil,/ )':; (1}max

A lll'AOil rdtio, Lr; or

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Suttt | *J l.th* | *Jr.* | *1\p* | I nducing fuclon | Limiting faclors |
| L(AK | *L;* lo", calion | 0 | max. | proton k-ak.hp, | =*J* o·(1) "ilhou |

(J) inhibition of the phn lllorylation­ palhway.L....,

analySIS, aerobic cell performance Is mt-quallty (mt-specific flux, *e.g.,* per c1trate synthase, CS) ti mes

OXPHOS /hW!.A OI'- mnx. high kt uehcally· ./p.by ))hO"'JlhOJ)'ICII toll-

'\timulatcd saluraling [ADP] pmh"y; or.J.o. hy FT-

respiration and[ri] capacity

Fl *H;* max , low optimal external .Ao, b)• H -capacity

ooncouplcd uncouplCT


rcspirution oonc.cntrut ion for

..-... {mt.Qudry II

p.Hfonn.afta • rm:flnction •

mt-quantlty, or mt-functlon ti mes mt-structure.

1861



max. .lo•.t·

ROX *Rox:* mm., 0 0 *Jo;..,Jt.* in non-ET- inh1bltwn of all ET- rct idual <h palhway tl31hwayc;.; or absence consumpt1on o1;idation of fuel substrates

reactions

() cost:: " MltoEAGLE


• ·-h---·--;;:;..::.:.- Join

COST Action CA15203

"""-- [www.mitoeagle.org/index.php/MitoEAGLE](http://www.mitoeagle.org/index.php/MitoEAGLE)



**E**volution **A**ge **G**ender




**L**ifestyle **E**nvironment

**Mission of the global MitoEAGLE network**

in collaboration with the Mitochondrial Physiology Society, MiP*s*

• Improve our knowledge on mitochondrial function in health and disease with regard to **E**volution, **A**ge, **G**ender, **L**ifestyle and **E**nvironment



• Interrelate studies across laboratories with the help of a MitoEAGLE data management system

• Provide standardized measures to link mitochondrial and

physiological performance to understand the myriad of factors that play a role in mitochondrial physiology

**Join the COST Action MitoEAGLE - contribute to the quality management network.**

More information:



[www.mitoeagle.org](http://www.mitoeagle.org/)



1862



Funded by the Horizon 2020 Framework Programme of the European Union